thiotepa has been researched along with Bladder Cancer in 318 studies
Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the role, if any, of one and five installations of intravesical thiotepa in the treatment of newly diagnosed superficial bladder cancer." | 9.07 | The effect of intravesical thiotepa on tumour recurrence after endoscopic treatment of newly diagnosed superficial bladder cancer. A further report with long-term follow-up of a Medical Research Council randomized trial. Medical Research Council Working P ( , 1994) |
| "This report presents the second interim analysis of data from a randomized prospective trial that compares the prophylactic effect of 15 intravesical instillations of 50 mg Doxorubicin (ADM), 50 mg of Thiotepa (TTPA), or 150 mg of Bacillus Calmette-Guérin (BCG) against recurrence and progression of superficial transitional cell bladder cancer." | 9.06 | Intravesical therapy comparing BCG, adriamycin, and thiotepa in 200 patients with superficial bladder cancer: a randomized prospective study. ( Cárcamo, P; Fiter, L; García Matres, MJ; Jimenez León, J; Martinez-Pineiro, JA; Martinez-Pineiro, L; Mosteiro, JA; Navarro, J, 1989) |
| "The influence of the instillation of thiotepa or doxorubicin hydrochloride into the bladder at the end of transurethral surgical treatment on the recurrence of bladder cancer was evaluated." | 9.05 | Influence of thiotepa and doxorubicin instillation at time of transurethral surgical treatment of bladder cancer on tumor recurrence: a prospective, randomized, double-blind, controlled trial. ( Leary, FJ; Myers, RP; Taylor, WF; Utz, DC; Zincke, H, 1983) |
| "In a prospective, randomized, stratified study with crossover design the effect of thiotepa was compared to that of mitomycin C when each was instilled intravesically immediately at the end of complete removal of superficial bladder cancer (stages Ta and Tis) and later on tumor recurrence." | 9.05 | Intravesical thiotepa and mitomycin C treatment immediately after transurethral resection and later for superficial (stages Ta and Tis) bladder cancer: a prospective, randomized, stratified study with crossover design. ( Benson, RC; Hilton, JF; Taylor, WF; Zincke, H, 1985) |
| "The National Bladder Cancer Group undertook a study to determine the effectiveness and toxicity of mitomycin in patients who failed on thiotepa." | 9.05 | Mitomycin for patients who have failed on thiotepa. The National Bladder Cancer Group. ( Barton, B; Hazra, TA; Heney, NM; Kluskens, L; Koontz, WW; Soloway, MS; Trump, DL, 1985) |
| "This report describes and presents some preliminary results from a prospective clinical investigation to determine the ablative effect of thiotepa (N,N',N''-triethylene phosphoramide) on superficial low-stage bladder cancer and the effectiveness of this agent in the prevention of recurrent or new tumors." | 9.04 | The role of intravesical thiotepa in the management of superficial bladder cancer. National Bladder Cancer Collaborative Group A. ( , 1977) |
| "Mitomycin-C (MMC) and thiotepa are intravesical agents effective in reducing the recurrence of low-grade noninvasive bladder cancer when instilled perioperatively." | 7.91 | Single-dose perioperative mitomycin-C versus thiotepa for low-grade noninvasive bladder cancer. ( Blodgett, G; Castle, EP; Chang, YH; Etzioni, DA; Faraj, K; Habermann, EB; Humphreys, MR; Rose, KM; Tyson Ii, MD, 2019) |
| "We describe a patient with chronic renal failure and transitional cell carcinoma, in whom a nephrogenic adenoma of the bladder was diagnosed after a course of intravesical thiotepa treatment." | 7.68 | Nephrogenic adenoma in a patient with chronic renal failure associated with intravesical treatment with thiotepa. ( Embon, OM; Gold, CH; Sazbon, A; Turani, H, 1990) |
| "Mitomycin C 40 mg in 40 ml water was administered intravesically every week for 8 consecutive weeks to 60 patients with superficial bladder cancer." | 7.67 | Mitomycin C intravesical therapy in noninvasive bladder cancer after failure on thiotepa. ( Block, NL; Brannen, G; Cummings, KB; Flanagan, M; Issell, BF; Levin, EA; Prout, GR; Soloway, MS; Summers, JL; Veenema, R, 1984) |
| "Cytotoxicity of thiotepa or doxorubicin hydrochloride in human bladder cancer cells was investigated alone and in combination with methylxanthines." | 7.67 | Enhanced lethality by methylxanthines in human bladder cancer cells treated with thiotepa. ( Fingert, HJ; Kindy, RL; Pardee, AB, 1984) |
| "We studied the incidence of myelosuppression and renal function in 33 patients treated by repeated resections of bladder tumors and thiotepa instillations for at least 26 months in the presence of vesicoureteral reflux." | 7.67 | Long-term intravesical thiotepa treatment in patients with superficial bladder tumors and vesicoureteral reflux. ( Glanz, I; Nissenkorn, I; Servadio, C; Vilikowski, E, 1985) |
| "A case of nearly exsanguinating bladder hemorrhage, occurring six months after intravesical thiotepa administration, is reported." | 7.67 | Intractable bladder hemorrhage requiring cystectomy after use of intravesical thiotepa. ( Friedman, NB; Kasimain, D; Kern, WH; Skinner, D; Treible, DP, 1987) |
| " These patients with progressive bladder carcinoma appeared to be unaffected by intravesical thiotepa in the dosage used." | 5.27 | Intravesical thiotepa prophylaxis of superficial bladder cancer. A follow-up study. ( Fosså, SD; Miller, A; Stenwig, AE, 1983) |
| "Vesicoureteral reflux was studied by retrograde cystograms in 75 patients with recurrent transitional cell carcinoma of the bladder." | 5.26 | Unanticipated vesicoureteral reflux: a possible sequela of long-term thio-tepa instillations to the bladder. ( Cytron, S; Glanz, I; Mukamel, E; Nissenkorn, I; Servadio, C, 1982) |
| "ThioTEPA is given intravesically in a variety of schedules to treat superficial bladder cancer." | 5.08 | ThioTEPA pharmacokinetics during intravesical chemotherapy: the influence of dose and volume of instillate on systemic uptake and dose rate to the tumour. ( Bibby, MC; Harland, S; Loadman, PM; Masters, JR; McDermott, BJ, 1996) |
| "To determine the role, if any, of one and five installations of intravesical thiotepa in the treatment of newly diagnosed superficial bladder cancer." | 5.07 | The effect of intravesical thiotepa on tumour recurrence after endoscopic treatment of newly diagnosed superficial bladder cancer. A further report with long-term follow-up of a Medical Research Council randomized trial. Medical Research Council Working P ( , 1994) |
| "A prospective randomized clinical trial was conducted by the National Bladder Cancer Group to compare thiotepa and mitomycin C in ablating residual Ta, T1 and TIS transitional cell carcinoma of the bladder." | 5.06 | Intravesical thiotepa versus mitomycin C in patients with Ta, T1 and TIS transitional cell carcinoma of the bladder: a phase III prospective randomized study. ( Barton, B; Hazra, T; Heney, NM; Koontz, WW; Soloway, M; Trump, DL; Weinstein, RS, 1988) |
| "This report presents the second interim analysis of data from a randomized prospective trial that compares the prophylactic effect of 15 intravesical instillations of 50 mg Doxorubicin (ADM), 50 mg of Thiotepa (TTPA), or 150 mg of Bacillus Calmette-Guérin (BCG) against recurrence and progression of superficial transitional cell bladder cancer." | 5.06 | Intravesical therapy comparing BCG, adriamycin, and thiotepa in 200 patients with superficial bladder cancer: a randomized prospective study. ( Cárcamo, P; Fiter, L; García Matres, MJ; Jimenez León, J; Martinez-Pineiro, JA; Martinez-Pineiro, L; Mosteiro, JA; Navarro, J, 1989) |
| "In a prospective, randomized, stratified study with crossover design the effect of thiotepa was compared to that of mitomycin C when each was instilled intravesically immediately at the end of complete removal of superficial bladder cancer (stages Ta and Tis) and later on tumor recurrence." | 5.05 | Intravesical thiotepa and mitomycin C treatment immediately after transurethral resection and later for superficial (stages Ta and Tis) bladder cancer: a prospective, randomized, stratified study with crossover design. ( Benson, RC; Hilton, JF; Taylor, WF; Zincke, H, 1985) |
| "The influence of the instillation of thiotepa or doxorubicin hydrochloride into the bladder at the end of transurethral surgical treatment on the recurrence of bladder cancer was evaluated." | 5.05 | Influence of thiotepa and doxorubicin instillation at time of transurethral surgical treatment of bladder cancer on tumor recurrence: a prospective, randomized, double-blind, controlled trial. ( Leary, FJ; Myers, RP; Taylor, WF; Utz, DC; Zincke, H, 1983) |
| "The National Bladder Cancer Group undertook a study to determine the effectiveness and toxicity of mitomycin in patients who failed on thiotepa." | 5.05 | Mitomycin for patients who have failed on thiotepa. The National Bladder Cancer Group. ( Barton, B; Hazra, TA; Heney, NM; Kluskens, L; Koontz, WW; Soloway, MS; Trump, DL, 1985) |
| "This paper reports the preliminary results of an ongoing clinical trial in patients with category T1 bladder cancer who are randomized after transurethral resection to receive either thiotepa, VM-26, or no treatment." | 5.04 | Adjuvant therapy of T1 bladder carcinoma: preliminary results of an EORTC randomized study. ( De Pauw, M; Denis, L; Lachand, A; Pavone-Macaluso, M; Robinson, M; Schulman, C; Smith, P; Staquet, M; Sylvester, R, 1978) |
| "This report describes and presents some preliminary results from a prospective clinical investigation to determine the ablative effect of thiotepa (N,N',N''-triethylene phosphoramide) on superficial low-stage bladder cancer and the effectiveness of this agent in the prevention of recurrent or new tumors." | 5.04 | The role of intravesical thiotepa in the management of superficial bladder cancer. National Bladder Cancer Collaborative Group A. ( , 1977) |
| "Intravesical therapy of superficial bladder cancer has been in routine use since the introduction of thiotepa in 1961." | 4.80 | Improved patient outcomes with BCG immunotherapy vs. chemotherapy - Swedish and worldwide experience. ( Malmström, P, 2000) |
| "To review the results of clinical trials and adverse drug effects of thiotepa, BCG vaccine, mitomycin, and doxorubicin, which are used as adjuvant intravesical therapy for superficial bladder cancer." | 4.78 | Adjuvant intravesical therapy for superficial bladder cancer. ( Batts, CN, 1992) |
| "Mitomycin-C (MMC) and thiotepa are intravesical agents effective in reducing the recurrence of low-grade noninvasive bladder cancer when instilled perioperatively." | 3.91 | Single-dose perioperative mitomycin-C versus thiotepa for low-grade noninvasive bladder cancer. ( Blodgett, G; Castle, EP; Chang, YH; Etzioni, DA; Faraj, K; Habermann, EB; Humphreys, MR; Rose, KM; Tyson Ii, MD, 2019) |
| "We describe a patient with chronic renal failure and transitional cell carcinoma, in whom a nephrogenic adenoma of the bladder was diagnosed after a course of intravesical thiotepa treatment." | 3.68 | Nephrogenic adenoma in a patient with chronic renal failure associated with intravesical treatment with thiotepa. ( Embon, OM; Gold, CH; Sazbon, A; Turani, H, 1990) |
| "The in vitro cytotoxicities of the four drugs most frequently used for intravesical chemotherapy (Adriamycin, epodyl, mitomycin C, Thiotepa) and epirubicin were compared using monolayers and multicellular tumor spheroids of the human bladder cancer cell line, MGH-U1." | 3.67 | Sensitivities of monolayers and spheroids of the human bladder cancer cell line MGH-U1 to the drugs used for intravesical chemotherapy. ( Hofstadter, F; Jenkins, WE; Knuchel, R; Masters, JR, 1989) |
| "We present a series of 13 patients with diffuse carcinoma in situ (CIS) of the bladder who failed an initial induction course of intravesical therapy with Mitomycin C, thiotepa, doxorubicin or Bacillus Calmette Guérin (BCG)." | 3.67 | Conservative treatment of diffuse carcinoma in situ of the bladder with repeated courses of intravesical therapy. ( deKernion, JB; Mukamel, E, 1989) |
| " A human bladder cancer cell line was exposed to a range of concentrations of the four drugs commonly used to treat superficial bladder cancer (adriamycin, epodyl, mitomycin-c, thiotepa) for periods of 30, 60 and 120 min." | 3.67 | Intravesical chemotherapy: in vitro studies on the relationship between dose and cytotoxicity. ( English, PJ; Hepburn, PJ; Masters, JR; Parris, CN; Walker, MC, 1986) |
| "Tween 80 was shown to enhance significantly the cytotoxic activities of the four drugs (adriamycin, epodyl, mitomycin-c, thiotepa) most frequently administered intravesically to treat superficial bladder cancer." | 3.67 | Intravesical chemotherapy: combination with Tween 80 increases cytotoxicity in vitro. ( English, P; Masters, JR; Newman, B; Parris, CN; Riddle, P; Walker, MC, 1987) |
| "We describe an unusual case of pruritus after intravesical thiotepa, and diaphoresis, shortness of breath, chills and pruritus following intravesical doxorubicin therapy." | 3.67 | Generalized hypersensitivity reaction to intravesical thiotepa and doxorubicin. ( Lee, M; Sharifi, R, 1987) |
| "A case of nearly exsanguinating bladder hemorrhage, occurring six months after intravesical thiotepa administration, is reported." | 3.67 | Intractable bladder hemorrhage requiring cystectomy after use of intravesical thiotepa. ( Friedman, NB; Kasimain, D; Kern, WH; Skinner, D; Treible, DP, 1987) |
| "Mitomycin C 40 mg in 40 ml water was administered intravesically every week for 8 consecutive weeks to 60 patients with superficial bladder cancer." | 3.67 | Mitomycin C intravesical therapy in noninvasive bladder cancer after failure on thiotepa. ( Block, NL; Brannen, G; Cummings, KB; Flanagan, M; Issell, BF; Levin, EA; Prout, GR; Soloway, MS; Summers, JL; Veenema, R, 1984) |
| "We studied the incidence of myelosuppression and renal function in 33 patients treated by repeated resections of bladder tumors and thiotepa instillations for at least 26 months in the presence of vesicoureteral reflux." | 3.67 | Long-term intravesical thiotepa treatment in patients with superficial bladder tumors and vesicoureteral reflux. ( Glanz, I; Nissenkorn, I; Servadio, C; Vilikowski, E, 1985) |
| "Cytotoxicity of thiotepa or doxorubicin hydrochloride in human bladder cancer cells was investigated alone and in combination with methylxanthines." | 3.67 | Enhanced lethality by methylxanthines in human bladder cancer cells treated with thiotepa. ( Fingert, HJ; Kindy, RL; Pardee, AB, 1984) |
| " With human bladder cancer cells in culture, cytotoxicity of thiotepa was increased up to 10-fold (P less than 0." | 3.67 | In vivo and in vitro enhanced antitumor effects by pentoxifylline in human cancer cells treated with thiotepa. ( Alley, MC; Chen, ZY; Fingert, HJ; Googe, PB; Pardee, AB; Pu, AT, 1988) |
| "We investigated the effectiveness of intravesically administered drugs on the tumor incidence and tumor size in a FANFT-induced animal model for bladder cancer." | 3.66 | Single and sequential combination intravesical chemotherapy of murine bladder cancer. ( McCallum, LW; Murphy, WM; Nissenkorn, I; Soloway, MS, 1982) |
| "A pharmacokinetic study of randomised crossover design was carried out in which eight patients with recurrent stage pTa or pT1 transitional cell carcinoma of the bladder were given thioTEPA (30 mg) in distilled water or in 10% (v/v) Tween 80 (30 ml) intravesically for 2 h, followed 3 months later by the alternative treatment." | 2.67 | ThioTEPA pharmacokinetics during intravesical chemotherapy and the influence of Tween 80. ( Bibby, MC; Fenwick, E; Jenkins, WE; Loadman, PM; Masters, JR; McDermott, BJ; Mundy, AR; Shah, PJ, 1990) |
| "The treatment of bladder cancer is one of the most active areas of clinical cancer research." | 2.66 | Approaches to the treatment of bladder cancer at Stanford. ( Torti, FM, 1987) |
| "Superficial bladder cancer can be treated surgically, but patients are at high risk for recurrence." | 2.43 | Bladder cancer: current optimal intravesical treatment. ( Hale, K; Lamm, DL; McGee, WR, 2005) |
| " On the other hand, bacillus Calmette-Guerin (BCG) currently appears to be the most effective agent for intravesical use, especially in patients with high grade and stage neoplasms but the optimum strain, dosage and duration schedule have not been determined." | 2.41 | Intravesical therapy of superficial bladder cancer. ( Melekos, MD; Moutzouris, GD, 2000) |
| "Superficial bladder cancer accounts for approximately 70% to 80% of all newly diagnosed bladder cancers." | 2.41 | An overview of the treatment of superficial bladder cancer. Intravesical chemotherapy. ( Duque, JL; Loughlin, KR, 2000) |
| "Close to 75% of all bladder tumors are confined to the urothelium (stage Ta, or carcinoma in situ), and nearly 30% of papillary tumors invade the lamina propria (stage T1)." | 2.41 | Intravesical therapy for superficial bladder cancer. ( Baselli, EC; Greenberg, RE, 2000) |
| "The management of superficial bladder cancer has advanced significantly in recent years." | 2.39 | BCG in perspective: advances in the treatment of superficial bladder cancer. ( Lamm, DL, 1995) |
| "The decision to treat superficial bladder cancer with intravesical therapy should be predicated primarily on disease stage and grade as well as the patient's clinical history." | 2.39 | Intravesical chemotherapy versus immunotherapy for superficial bladder cancer. ( Huben, RP, 1996) |
| "More than 90 percent of bladder cancers are transitional cell carcinoma (TCC)." | 2.38 | Managing superficial bladder cancer: an overview. ( Soloway, MS, 1992) |
| "7." | 2.38 | Rationale for intravesical chemotherapy in the treatment and prophylaxis of superficial transitional cell carcinoma. ( Jordan, AM; Murphy, WM; Soloway, MS, 1989) |
| " Different dosage schedules and methods require further study." | 2.38 | Intravesical chemotherapy. Treatment selection, techniques, and results. ( Richie, JP, 1992) |
| "Management of the superficial bladder cancer patient consists of two complementary but separate therapeutic goals: treatment of the existing tumor(s) and prevention of tumor recurrence." | 2.37 | The biology and treatment of superficial bladder cancer. ( Lum, BL; Torti, FM, 1984) |
| "Most patients with bladder cancer initially present with localized, potentially curable tumours." | 2.36 | Treatment of superficial bladder cancer. ( Morales, A, 1980) |
| "As an example of application, a set of bladder cancer data is analyzed to illustrate the proposed methods." | 1.36 | Empirical receiver operating characteristic curve for two-sample comparison with cure fractions. ( Zhao, X; Zhou, X, 2010) |
| "One hundred fifty-five patients with urinary bladder cancer who were not suitable for radical surgery were treated with full-course radiotherapy, 6600 cGy in 9 weeks, split-course." | 1.28 | Recurrence and treatment of urinary bladder cancer after failure in radiotherapy. ( Salminen, E, 1990) |
| "Superficial bladder cancer has a good prognosis compared with invasive bladder cancer." | 1.28 | [Superficial bladder cancer: prophylaxis of recurrence and progression]. ( Akaza, H; Koiso, K; Miyanaga, N, 1991) |
| " PDT combined with either adriamycin, MMC or BCG, produced a greater retardation in the growth of the MBT-2 tumor than monotherapy with adriamycin, MMC, BCG or PDT." | 1.28 | Effects of photodynamic therapy in combination with intravesical drugs in a murine bladder tumor model. ( Cho, YH; Smith, JA; Straight, RC, 1992) |
| "Recurrent bladder tumors developed subsequently in 80 per cent of the patients in group 1, 42." | 1.27 | A comparison of treatment methods for the prophylaxis of recurrent superficial bladder tumors. ( Lemos, GC; Rodrigues Netto Júnior, N, 1983) |
| "The incidence of bladder cancer is slowly rising, which may be due in part to the increasing use of chemicals in every phase of our modern society." | 1.27 | Bladder cancer. Management of an increasingly common tumor. ( Soloway, MS, 1983) |
| "The therapeutic principles of bladder cancer are reviewed in the fields of surgery, radiation and chemotherapy." | 1.27 | [Bladder cancer]. ( Sakatoku, J; Yamamoto, N, 1983) |
| " These patients with progressive bladder carcinoma appeared to be unaffected by intravesical thiotepa in the dosage used." | 1.27 | Intravesical thiotepa prophylaxis of superficial bladder cancer. A follow-up study. ( Fosså, SD; Miller, A; Stenwig, AE, 1983) |
| "Urine from patients with bladder cancer before treatment had osmolalities in the range 187 to 852 mOsm." | 1.27 | Intravesical chemotherapy: studies on the relationship between osmolality and cytotoxicity. ( Groos, E; Masters, JR, 1986) |
| "The effects of interferon alone and in combination with either adriamycin, mitomycin C or thiotepa were evaluated for antiproliferative activity for the mouse bladder tumor, MBT-2." | 1.27 | Effects of interferon in combination with cytotoxic drugs on mouse bladder tumor (MBT-2) growth in vitro and in vivo. ( Bahnson, R; Ratliff, TL, 1988) |
| "Patients with multiple bladder tumors, bladder tumors inaccessible to endoscopic resection, or lesions too extensive to completely resect, or with medial contraindications for endoscopic resection procedures, were included in these studies." | 1.27 | Combined thiotepa and mitomycin C instillation therapy for low-grade superficial bladder tumor. ( Gonder, M; Hu, KN; Khan, AS; Kim, A; Soroff, H, 1985) |
| "Thus, it appears that the status of bladder cancer can be monitored successfully by an assessment of urinary cytology in the context of long-term treatment and prophylaxis with this agent." | 1.27 | Thiotepa effects on urinary cytology in the interpretation of transitional cell cancer. ( Droller, MJ; Erozan, YS, 1985) |
| "Recurrent transitional cell carcinoma was treated with prophylactic intravesical thio-tepa in 22 cases." | 1.26 | Intravesical thio-tepa in the immediate postoperative period in patients with recurrent transitional cell carcinoma of the bladder. ( Gavrell, GJ; Leblanc, GA; Lewis, RW; Meehan, WL, 1978) |
| "Patients with recurrent superficial bladder tumors have been treated by vesical and intradermal administration of Bacillus Calmette-Guerin." | 1.26 | Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. ( Bruce, AW; Eidinger, D; Morales, A, 1976) |
| "Treatment of superficial low-grade bladder cancer often incorporates intravesical instillations of the alkylating agent thio-TEPA." | 1.26 | Intravesical thio-tepa: a study of 3H-thymidine uptake in normal urothelium and FANFT-induced tumors in rats. ( Daly, JJ; Irwin, RJ; Nieh, PT; Prout, GR, 1979) |
| "In order to reduce the recurrence rate of bladder tumours, 78 patients with bladder tumours have been treated since November 1973 with topical Thio-TEPA bladder instillations." | 1.26 | The prophylactic use of Thio-TEPA, an adjuvant in the treatment of bladder tumours. ( Dobrzecki, W; Kaczmarek, A, 1977) |
| "Vesicoureteral reflux was studied by retrograde cystograms in 75 patients with recurrent transitional cell carcinoma of the bladder." | 1.26 | Unanticipated vesicoureteral reflux: a possible sequela of long-term thio-tepa instillations to the bladder. ( Cytron, S; Glanz, I; Mukamel, E; Nissenkorn, I; Servadio, C, 1982) |
| "The treatment of 101 male patients with venereal warts is described." | 1.26 | Treatment of Condyloma acuminata in male patients. ( Alfthan, O; Kiistala, U; Lassus, A; Pyrhönen, S; Vuori, J, 1977) |
| " Continuing maintenance therapy was required in the majority but, with the passage of time, the dosage could be progressively reduced, suggesting a cumulative effect of treatment." | 1.26 | Early multiple-dose adjuvant thiotepa in the control of multiple and rapid T1 tumour neogenesis. ( Blandy, JP; England, HR; Flynn, JT; Paris, AM, 1981) |
| "Thiotepa treatments should be limited to 90 mg/mo and protracted therapy avoided in elderly men." | 1.26 | Hematologic effects of intravesicular thiotepa therapy for bladder carcinoma. ( Coleman, M; Hollister, D, 1980) |
| "Thiotepa was found to produce marked acantholysis in 43 per cent of those studied." | 1.26 | The effect of chemotherapeutic agents on the ultrastructure of transitional cell carcinoma in tissue culture. ( Adelstein, E; Haigh, J; Khare, N; Oxenhandler, R; Ross, G; Weaver, D, 1980) |
| "The prevention of recurrences of bladder cancer was attemped in 48 patients by means of the combined intravesical instillation of thio-tepa and urokinase and in 28 patients through the instillation of thio-tepa alone." | 1.25 | The prophylactic use of thio-tepa and urokinase in transitional cell carcinoma of the bladder: a preliminary report. ( Hisazumi, H; Misaki, T; Miyazaki, K; Naito, K; Uchibayashi, T, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 264 (83.02) | 18.7374 |
| 1990's | 32 (10.06) | 18.2507 |
| 2000's | 9 (2.83) | 29.6817 |
| 2010's | 13 (4.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Faraj, K | 1 |
| Chang, YH | 1 |
| Rose, KM | 1 |
| Habermann, EB | 1 |
| Etzioni, DA | 1 |
| Blodgett, G | 1 |
| Castle, EP | 1 |
| Humphreys, MR | 1 |
| Tyson Ii, MD | 1 |
| Chen, F | 1 |
| Chen, K | 1 |
| Baetschmann, G | 1 |
| Winkelmann, R | 1 |
| Zhao, X | 2 |
| Deng, S | 1 |
| Liu, L | 2 |
| Tan, KS | 1 |
| French, B | 1 |
| Troxel, AB | 1 |
| Sylvester, RJ | 1 |
| Oosterlinck, W | 2 |
| Holmang, S | 1 |
| Sydes, MR | 1 |
| Birtle, A | 1 |
| Gudjonsson, S | 1 |
| De Nunzio, C | 1 |
| Okamura, K | 1 |
| Kaasinen, E | 1 |
| Solsona, E | 1 |
| Ali-El-Dein, B | 1 |
| Tatar, CA | 1 |
| Inman, BA | 1 |
| N'Dow, J | 1 |
| Oddens, JR | 1 |
| Babjuk, M | 1 |
| Dardis, C | 1 |
| Milton, K | 1 |
| Ashby, L | 1 |
| Pullenayegum, EM | 1 |
| Lu, DD | 1 |
| Boorjian, SA | 1 |
| Raman, JD | 1 |
| Zhou, X | 1 |
| Abd-Elfattah, EF | 1 |
| Puchner, PJ | 1 |
| Veenema, RJ | 7 |
| Tomashefsky, P | 2 |
| Pinzus, T | 1 |
| Tannenbaum, T | 1 |
| Fay, MP | 1 |
| Shih, JH | 1 |
| Barlow, LJ | 1 |
| Benson, MC | 1 |
| JONES, HC | 2 |
| SWINNEY, J | 1 |
| DEAN, AL | 4 |
| ROBERTS, M | 2 |
| FINGERHUT, B | 2 |
| CHOWHURY, BK | 1 |
| TARASSOLY, H | 1 |
| VIANNA, JB | 1 |
| BOURDIN, JS | 1 |
| SARACINO, RT | 1 |
| LILLE, I | 1 |
| GABAY, F | 1 |
| RAVINA, A | 1 |
| ESQUIVEL, EL | 1 |
| MACKENZIE, AR | 1 |
| WHITMORE, WF | 2 |
| GEORGACOPULO, P | 1 |
| STANCANELLI, V | 1 |
| MOTTA, G | 1 |
| PADOVAN, Q | 1 |
| ROBERTS, DI | 1 |
| Startsev, V | 1 |
| Pouline, I | 1 |
| Lamm, DL | 3 |
| McGee, WR | 1 |
| Hale, K | 1 |
| Burgués, JP | 1 |
| Gómez, L | 1 |
| Pontones, JL | 1 |
| Vera, CD | 2 |
| Jiménez-Cruz, JF | 1 |
| Ozonas, M | 1 |
| Shrivastav, S | 1 |
| Paulson, DF | 2 |
| Weisenthal, LM | 1 |
| Lalude, AO | 1 |
| Miller, JB | 1 |
| Spaulding, JT | 1 |
| Uchibayashi, T | 2 |
| Ohmori, H | 2 |
| Rodrigues Netto Júnior, N | 1 |
| Lemos, GC | 1 |
| Soloway, MS | 26 |
| Zincke, H | 5 |
| Utz, DC | 4 |
| Taylor, WF | 2 |
| Myers, RP | 1 |
| Leary, FJ | 1 |
| Dalesio, O | 3 |
| Schulman, CC | 4 |
| Sylvester, R | 5 |
| De Pauw, M | 4 |
| Robinson, M | 3 |
| Denis, L | 4 |
| Smith, P | 3 |
| Viggiano, G | 4 |
| Longo, FW | 1 |
| Rivin, BD | 1 |
| Tannenbaum, M | 1 |
| Toulouse, J | 1 |
| Bouffier, B | 1 |
| Etievent, JP | 1 |
| Bittard, M | 1 |
| Lum, BL | 3 |
| Sakatoku, J | 1 |
| Yamamoto, N | 1 |
| Fosså, SD | 2 |
| Miller, A | 1 |
| Stenwig, AE | 1 |
| Murphy, WM | 7 |
| Easton, DJ | 1 |
| Poon, MA | 1 |
| Nissenkorn, I | 4 |
| Slutzker, D | 1 |
| Schujman, E | 1 |
| Servadio, C | 5 |
| Prout, GR | 10 |
| Koontz, WW | 6 |
| Coombs, LJ | 1 |
| Hawkins, IR | 1 |
| Friedell, GH | 2 |
| Ford, KS | 1 |
| Pavone-Macaluso, M | 11 |
| Tripi, M | 1 |
| Ingargiola, GB | 1 |
| Shapiro, A | 1 |
| Ratliff, TL | 2 |
| Oakley, DM | 1 |
| Catalona, WJ | 1 |
| Green, DF | 1 |
| Robinson, MR | 1 |
| Glashan, R | 1 |
| Newling, D | 1 |
| Smith, PH | 4 |
| Issell, BF | 1 |
| Cummings, KB | 1 |
| Brannen, G | 1 |
| Veenema, R | 1 |
| Flanagan, M | 2 |
| Block, NL | 1 |
| Summers, JL | 1 |
| Levin, EA | 1 |
| Danielli, L | 1 |
| Glezerman, M | 1 |
| Beyar, H | 1 |
| Torti, FM | 3 |
| Simpson, WG | 2 |
| Tseng, MT | 2 |
| Anderson, KC | 1 |
| Harty, JI | 2 |
| Fingert, HJ | 3 |
| Kindy, RL | 1 |
| Pardee, AB | 3 |
| Horn, Y | 2 |
| Eidelman, A | 2 |
| Walach, N | 2 |
| Yuval, E | 1 |
| Markowitz, A | 1 |
| Cifuentes Delatte, L | 1 |
| García de la Peña, E | 1 |
| Vela Navarrete, R | 1 |
| Martínez-Piñeiro, JA | 3 |
| Kopp, J | 1 |
| Whelan, P | 1 |
| Flynn, C | 1 |
| Ramsden, C | 1 |
| Akdaş, A | 1 |
| Kirkali, Z | 1 |
| Sengör, F | 1 |
| Ilker, Y | 1 |
| Taşar, C | 1 |
| Huang, CH | 1 |
| Asahi, T | 1 |
| Matsumura, Y | 1 |
| Tanahashi, T | 1 |
| Yoshimoto, J | 1 |
| Kaneshige, T | 1 |
| Fujita, Y | 1 |
| Weaver, D | 1 |
| Khare, N | 1 |
| Haigh, J | 1 |
| Adelstein, E | 1 |
| Oxenhandler, R | 1 |
| Ross, G | 2 |
| James, K | 1 |
| Alroy, J | 1 |
| Miller, AW | 1 |
| Morales, A | 2 |
| Malling, N | 2 |
| Sørensen, SS | 1 |
| Saito, K | 1 |
| Fukushima, S | 1 |
| Takahashi, Y | 1 |
| Takai, S | 1 |
| Kato, T | 5 |
| Nemoto, R | 3 |
| Hollister, D | 1 |
| Coleman, M | 1 |
| Smith, W | 1 |
| Frable, WJ | 1 |
| Minnis, JE | 1 |
| Sauvage, R | 1 |
| Ghosal, SK | 1 |
| Sen, DK | 1 |
| Ilian, M | 1 |
| Crabtree, WN | 1 |
| Finebaum, PJ | 1 |
| Barrett, N | 1 |
| Kulkarni, JN | 1 |
| Kamat, MR | 1 |
| Juvekar, RL | 1 |
| England, HR | 1 |
| Flynn, JT | 1 |
| Paris, AM | 1 |
| Blandy, JP | 1 |
| McCallum, LW | 1 |
| Homonnai, TZ | 1 |
| Paz, G | 1 |
| Mukamel, E | 3 |
| Glanz, I | 2 |
| Cytron, S | 1 |
| Griffin, PP | 1 |
| Nocks, BN | 2 |
| DeFuria, MD | 1 |
| Daly, JJ | 3 |
| Brosman, SA | 2 |
| Agnelli, G | 1 |
| de Cunto, M | 1 |
| Gresele, P | 1 |
| del Favero, A | 1 |
| Baumgartner, G | 1 |
| Hofmann, W | 1 |
| Langkopf, B | 1 |
| Kianifard, F | 1 |
| Gallo, PP | 1 |
| Bretheau, D | 1 |
| Lechevallier, E | 1 |
| Jean, F | 1 |
| Rampal, M | 2 |
| Coulange, C | 1 |
| Borgmann, V | 1 |
| al-Abadi, H | 1 |
| Friedrichs, R | 1 |
| Nagel, R | 1 |
| Masters, JR | 8 |
| McDermott, BJ | 2 |
| Harland, S | 1 |
| Bibby, MC | 2 |
| Loadman, PM | 2 |
| Huben, RP | 3 |
| Malmström, P | 1 |
| Melekos, MD | 1 |
| Moutzouris, GD | 1 |
| Duque, JL | 1 |
| Loughlin, KR | 1 |
| Baselli, EC | 1 |
| Greenberg, RE | 1 |
| Ghosh, D | 1 |
| Lin, DY | 1 |
| Lindsey, JK | 1 |
| Yang, D | 1 |
| Li, S | 1 |
| Wang, H | 1 |
| Li, X | 1 |
| Liu, S | 1 |
| Han, W | 1 |
| Hao, J | 1 |
| Zhang, H | 1 |
| Oravisto, KJ | 2 |
| Mäntylä, M | 1 |
| Goĭkhberg, MI | 1 |
| Romanenko, AM | 1 |
| Zaparin, VK | 1 |
| Klimenko, IA | 1 |
| Edsmyr, F | 2 |
| Andersson, L | 1 |
| Kaczmarek, A | 4 |
| Ishikawa, K | 2 |
| Irwin, RJ | 3 |
| Gavrell, GJ | 1 |
| Lewis, RW | 1 |
| Meehan, WL | 1 |
| Leblanc, GA | 1 |
| Grossman, HB | 1 |
| Taya, T | 1 |
| Nieh, PT | 3 |
| Schulman, C | 1 |
| Lachand, A | 1 |
| Staquet, M | 3 |
| Csellár, M | 1 |
| Csontai, A | 1 |
| Carter, SK | 1 |
| Wasserman, TH | 1 |
| Okada, K | 1 |
| Kiyotaki, S | 1 |
| Kawazoe, K | 1 |
| Sato, Y | 1 |
| Kinoshita, R | 1 |
| Farrow, GM | 2 |
| Rife, CC | 1 |
| Greene, LF | 1 |
| Delzotto, L | 1 |
| Marchini, M | 1 |
| Barbui, PE | 1 |
| Okajima, E | 3 |
| Motomiya, Y | 1 |
| Ishuin, M | 1 |
| Ikuma, S | 1 |
| Ohara, S | 2 |
| Dobrzecki, W | 2 |
| Vuori, J | 1 |
| Alfthan, O | 1 |
| Pyrhönen, S | 1 |
| Kiistala, U | 1 |
| Lassus, A | 1 |
| Fournier, R | 1 |
| Viville, C | 1 |
| Heaney, JA | 1 |
| Heney, NM | 5 |
| Byar, D | 1 |
| Blackard, C | 1 |
| Alimi, JC | 1 |
| Pons, G | 1 |
| Fiquet, JM | 1 |
| Boyd, PJ | 2 |
| Burnand, KG | 2 |
| Hisazumi, H | 1 |
| Naito, K | 1 |
| Misaki, T | 1 |
| Miyazaki, K | 1 |
| Bessman, JD | 1 |
| Johnson, RK | 1 |
| Goldin, A | 1 |
| Martino, C | 1 |
| Mayo, ME | 1 |
| Shuttleworth, KE | 1 |
| Lloyd-Davies, RW | 1 |
| Eidinger, D | 1 |
| Bruce, AW | 1 |
| Gebbia, N | 3 |
| Schmidt, JD | 1 |
| Jacobo, EC | 1 |
| Weinstein, SH | 1 |
| Rozencweig, M | 1 |
| Kenis, Y | 1 |
| Wang, SH | 1 |
| Hirao, Y | 2 |
| Ozono, S | 2 |
| Samma, S | 1 |
| Sasaki, K | 1 |
| Hiramatsu, T | 2 |
| Babaya, K | 1 |
| Watanabe, S | 2 |
| Maruyama, Y | 1 |
| Batts, CN | 1 |
| Droller, MJ | 4 |
| Flanigan, RC | 2 |
| Nseyo, UO | 1 |
| Bordalba Gómez, JR | 1 |
| Muñoz Segui, J | 1 |
| Aguilo, F | 1 |
| Gil Vernet, A | 1 |
| Vigues, F | 1 |
| Lopez Costea, MA | 1 |
| Serrallach, N | 1 |
| Cho, YH | 1 |
| Straight, RC | 1 |
| Smith, JA | 1 |
| Bouffioux, C | 1 |
| Vergison, B | 1 |
| Keuppens, F | 1 |
| Cheuvart, B | 1 |
| Richie, JP | 1 |
| Thrasher, JB | 1 |
| Crawford, ED | 1 |
| Jenkins, WE | 2 |
| Fenwick, E | 1 |
| Shah, PJ | 1 |
| Mundy, AR | 1 |
| Salminen, E | 1 |
| Miyanaga, N | 1 |
| Akaza, H | 1 |
| Koiso, K | 1 |
| Tarkington, M | 1 |
| Sommers, CL | 1 |
| Gelmann, EP | 1 |
| Tefft, MC | 1 |
| Lynch, JH | 1 |
| Foo, KT | 1 |
| Tan, EC | 1 |
| Tung, KH | 1 |
| Tock, EP | 1 |
| Sánchez de la Muela, P | 1 |
| Rosell, D | 1 |
| Agüera, L | 1 |
| De Castro, F | 1 |
| Isa, W | 1 |
| Robles, JE | 1 |
| Zudaire, JJ | 1 |
| Berián, JM | 1 |
| Seraphim, LA | 1 |
| Perrapato, SD | 1 |
| Slocum, HK | 2 |
| Rustum, YM | 2 |
| Jiménez León, J | 2 |
| Martínez-Piñeiro, L | 2 |
| Fiter, L | 2 |
| Mosteiro, JA | 2 |
| Navarro, J | 2 |
| García Matres, MJ | 2 |
| Cárcamo, P | 2 |
| Embon, OM | 1 |
| Turani, H | 1 |
| Gold, CH | 1 |
| Sazbon, A | 1 |
| Vera-Donoso, CD | 1 |
| Llopis, B | 4 |
| Oliver, F | 1 |
| Gallego, J | 4 |
| Ruiz, J | 1 |
| Vidal, J | 1 |
| Jiménez Cruz, JF | 1 |
| Trybula, M | 1 |
| King, M | 1 |
| Moroz, C | 1 |
| Kupfer, B | 1 |
| Lindner, A | 1 |
| Many, M | 1 |
| Bahnson, R | 1 |
| Russell, KJ | 1 |
| Koh, WJ | 1 |
| Russell, AH | 1 |
| Griffin, BR | 1 |
| Markette, KL | 1 |
| Tong, DY | 1 |
| Griffin, TW | 1 |
| Knuchel, R | 1 |
| Hofstadter, F | 1 |
| Irwin, R | 1 |
| Parmar, MK | 1 |
| Freedman, LS | 2 |
| Hargreave, TB | 1 |
| Tolley, DA | 1 |
| Egerdie, RB | 1 |
| Reid, G | 1 |
| Trachtenberg, J | 1 |
| deKernion, JB | 1 |
| Jordan, AM | 1 |
| Fisher, HA | 1 |
| Pan, JS | 1 |
| Greco, WR | 1 |
| Gaeta, JF | 1 |
| Giannone, L | 1 |
| Greco, FA | 1 |
| Hainsworth, JD | 1 |
| Weaver, DJ | 1 |
| Barrett, BA | 1 |
| Adelstein, EH | 1 |
| Mobley, WC | 1 |
| Loening, SA | 1 |
| Narayana, AS | 1 |
| Culp, DA | 1 |
| Chang, JD | 1 |
| Ellison, MF | 1 |
| Butler, KM | 1 |
| Gomella, LG | 1 |
| McRoberts, JW | 1 |
| Groos, E | 2 |
| Walker, L | 1 |
| Mompó, JA | 2 |
| Boronat, F | 3 |
| Alonso, M | 2 |
| Moreno, B | 2 |
| Jiménez, JF | 3 |
| Walker, MC | 2 |
| Parris, CN | 2 |
| Hepburn, PJ | 1 |
| English, PJ | 1 |
| Danil'chenko, SA | 1 |
| Shlopov, VG | 1 |
| Serniak, PS | 1 |
| Geev, IuV | 1 |
| Kubota, Y | 2 |
| Ballou, RJ | 1 |
| Lancina Martín, J | 1 |
| Monsalve Rodríguez, M | 1 |
| Gómez Cisneros, S | 1 |
| García Alonso, J | 1 |
| Zhang, SX | 1 |
| Deng, XZ | 1 |
| Tang, XD | 1 |
| Levin, DR | 1 |
| Moskovitz, B | 1 |
| Mazeman, E | 1 |
| Rigot, JM | 1 |
| Cracco, D | 1 |
| Sauvage, L | 1 |
| Newman, B | 1 |
| Riddle, P | 1 |
| English, P | 1 |
| Perry, A | 2 |
| Konowalchuk, TW | 1 |
| Elhilali, M | 1 |
| Mackillop, WJ | 1 |
| Gu, FL | 1 |
| Shi, T | 1 |
| Feng, T | 1 |
| Wu, JP | 1 |
| Lee, M | 1 |
| Sharifi, R | 1 |
| Silberberg, JM | 1 |
| Zarrabi, MH | 1 |
| Sánchez, A | 1 |
| Martínez, R | 1 |
| Mazeron, JJ | 1 |
| Abbou, CC | 1 |
| Chopin, D | 1 |
| Antiphon, P | 1 |
| Kouri, G | 1 |
| Lansiaux, P | 1 |
| Pierquin, B | 1 |
| Auvert, J | 1 |
| Kakizaki, H | 1 |
| Suzuki, H | 1 |
| Numasawa, K | 1 |
| Suzuki, K | 1 |
| Yoshida, K | 1 |
| Yamada, K | 1 |
| Aoyama, H | 1 |
| Hashimoto, M | 1 |
| Stanisic, TH | 1 |
| Donovan, JM | 1 |
| Lebouton, J | 1 |
| Graham, AR | 1 |
| Alter, AJ | 1 |
| Malek, GH | 1 |
| Gilloz, A | 1 |
| Sauvage, I | 1 |
| Gremillet, E | 1 |
| Héritier, P | 1 |
| Richard, A | 1 |
| el Hajj, E | 1 |
| Diez-Yanguas, J | 1 |
| Treible, DP | 1 |
| Skinner, D | 1 |
| Kasimain, D | 1 |
| Friedman, NB | 1 |
| Kern, WH | 1 |
| Wood, DP | 1 |
| Streem, SB | 1 |
| Levin, HS | 1 |
| Torelli, T | 1 |
| Leidi, GL | 1 |
| Corrada, P | 1 |
| Bacchioni, AM | 1 |
| Ordesi, G | 1 |
| Zanitzer, L | 1 |
| Campo, B | 1 |
| Pu, AT | 1 |
| Chen, ZY | 1 |
| Googe, PB | 1 |
| Alley, MC | 1 |
| Hardeman, SW | 1 |
| Novak, R | 1 |
| Kern, J | 1 |
| Fister, H | 1 |
| Trnski, D | 1 |
| Dimanovski, J | 1 |
| Kraus, O | 1 |
| Spiegelhalter, DJ | 1 |
| Barton, B | 2 |
| Soloway, M | 1 |
| Trump, DL | 2 |
| Hazra, T | 1 |
| Weinstein, RS | 1 |
| Davis, CS | 1 |
| Wei, LJ | 1 |
| Hu, KN | 1 |
| Kim, A | 1 |
| Khan, AS | 1 |
| Soroff, H | 1 |
| Gonder, M | 1 |
| Vilikowski, E | 1 |
| Erozan, YS | 1 |
| Yang, HP | 1 |
| Gao, YJ | 1 |
| Kluskens, L | 1 |
| Hazra, TA | 1 |
| Haas, JA | 1 |
| Benson, RC | 1 |
| Hilton, JF | 1 |
| Walsh, PC | 1 |
| Dretler, SP | 1 |
| Bredin, HC | 1 |
| Mount, BM | 1 |
| Schellhammer, PF | 1 |
| Lunglmayr, G | 7 |
| Czech, K | 5 |
| Weissenhofer, W | 1 |
| Kellner, G | 3 |
| Zeckert, F | 1 |
| Rutishauser, G | 2 |
| Klein, U | 1 |
| Tuchschmid, D | 1 |
| Luzuy, R | 1 |
| Bouzakoura, C | 1 |
| Zekert, F | 1 |
| Kierfeld, G | 1 |
| Mellin, P | 1 |
| Biondo, F | 1 |
| Rizzo, FP | 3 |
| Caramia, G | 3 |
| Rausa, L | 2 |
| Romas, NA | 1 |
| Berenbaum, MC | 1 |
| Sheard, CE | 1 |
| Reittie, JR | 1 |
| Bundick, RV | 1 |
| des Roseaux, M | 1 |
| Vacant, J | 1 |
| Beurton, D | 1 |
| Cukier, J | 1 |
| Archimbaud, JP | 1 |
| Calcat, P | 1 |
| Martel, JP | 1 |
| Navas, P | 1 |
| Grasset, D | 1 |
| Corrado, F | 1 |
| Lalanne, G | 1 |
| Pizza, GC | 1 |
| Furnari, S | 2 |
| Veroux, G | 1 |
| Mattea, E | 1 |
| Arena, E | 1 |
| Tessitore, V | 1 |
| Vecchioni, M | 1 |
| Gibson, GR | 2 |
| Orlin, I | 1 |
| Zingg, E | 3 |
| Sulmoni, A | 1 |
| Tomiyama, T | 1 |
| Li, R | 1 |
| Kim, K | 1 |
| Brendler, H | 1 |
| Stetsenko, DV | 1 |
| Cole, DR | 1 |
| Howley, T | 1 |
| Rowan, R | 1 |
| Dreyer, B | 1 |
| Tan, YL | 1 |
| Gonzalez, E | 1 |
| Rousselot, LM | 1 |
| Girgis, AS | 1 |
| Uson, AC | 3 |
| Edgren, B | 1 |
| Forsgren, L | 1 |
| Boström, H | 1 |
| Puscariu, V | 1 |
| Bunescu, U | 1 |
| Schileru, G | 1 |
| Abbassian, A | 1 |
| Wallace, DM | 2 |
| Wescott, JW | 1 |
| Bruce, D | 1 |
| Edgcomb, JH | 1 |
| Watkins, WE | 1 |
| Kozak, JA | 1 |
| Flanagan, MJ | 1 |
| Kaufman, JJ | 2 |
| Lichtenauer, P | 1 |
| Guttmann, R | 1 |
| Sagerman, RH | 1 |
| Ciardullo, L | 1 |
| Reuter, JH | 1 |
| Drew, JE | 1 |
| Marshall, VF | 1 |
| Rabkova, LM | 1 |
| Longo, F | 1 |
| Saito, S | 1 |
| Lattuca, C | 1 |
| Leone, G | 1 |
| Lazarev, IR | 1 |
| Enenko, IuA | 1 |
| Rodovich, VS | 1 |
| Dmitrenko, SI | 1 |
| Boman, J | 1 |
| Zingg, EJ | 1 |
| Pellet, A | 1 |
| Djulepa, J | 1 |
| Riddle, PR | 1 |
| Mitchell, RJ | 1 |
| Cappelaere, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prospective Cohort Study of Transurethral Resection of Bladder Tumor (TURBT) Combined With Adjuvant Intravenous GC Chemotherapy to Prevent Moderate-high Recurrence and Progression Risks of Muscle-invasive Bladder Cancer[NCT02716961] | 208 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | |||
| Intravesical Instillation Therapy With Bacillus Calmette-Guérin (BCG) and Sequential BCG and Electromotive Mitomycin-C (EMDA-MCC) in Patients With High-risk Non-muscle-invasive Bladder Carcinoma[NCT03664869] | Phase 3 | 300 participants (Anticipated) | Interventional | 2018-10-26 | Recruiting | ||
| The Difference of Two Year Recurrence Rate According to Anesthetic Method During Transurethral Resection of Bladder Mass in Patients With Non-muscle Invasive Bladder Cancer: Prospective, Randomized, Clinical Phase II Study[NCT03597087] | 289 participants (Anticipated) | Interventional | 2018-07-19 | Not yet recruiting | |||
| Comparison of the Therapeutic Effects of Different Injection Number of the Same Dose of Botulinum Toxin A on Overactive Bladder Syndrome[NCT01657409] | Phase 2 | 90 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
40 reviews available for thiotepa and Bladder Cancer
| Article | Year |
|---|---|
Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma
Topics: Administration, Intravesical; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitiona | 2016 |
Experience with newer intravesical chemotherapy for high-risk non-muscle-invasive bladder cancer.
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Deox | 2013 |
Bladder cancer: current optimal intravesical treatment.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Cystectomy | 2005 |
Intravesical chemotherapy in the United States. An overview.
Topics: BCG Vaccine; Bleomycin; Carcinoma in Situ; Clinical Trials as Topic; Doxorubicin; Humans; Mitomycin; | 1983 |
Treatment of superficial carcinoma of the bladder.
Topics: Antineoplastic Agents; BCG Vaccine; Bleomycin; Carcinoma in Situ; Carcinoma, Transitional Cell; Comb | 1984 |
Intravesical chemotherapy of superficial bladder cancer.
Topics: Absorption; Animals; Antineoplastic Agents; BCG Vaccine; Carcinoma in Situ; Doxorubicin; Endoscopy; | 1983 |
Current topics in the pathology of bladder cancer.
Topics: Carcinoma in Situ; Carcinoma, Transitional Cell; Chromosome Aberrations; Chromosomes, Human, 1-3; Cy | 1983 |
The biology and treatment of superficial bladder cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; BCG Vaccine; Carcinoma, Squamous Cell; Carcinoma, Trans | 1984 |
Intravesical chemotherapy in the management of superficial bladder tumors.
Topics: Antineoplastic Agents; BCG Vaccine; Doxorubicin; Humans; Mitomycins; Neoplasm Recurrence, Local; Thi | 1984 |
Rationale for intensive intravesical chemotherapy.
Topics: Antineoplastic Agents; BCG Vaccine; Humans; Mitomycins; Neoplasm Recurrence, Local; Thiotepa; Urinar | 1984 |
Intravesical chemotherapy.
Topics: Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Clinical Trials as Topic; Combined | 1984 |
Intravesical and systemic chemotherapy in the management of superficial bladder cancer.
Topics: Administration, Topical; Aged; Antineoplastic Agents; Biopsy; Carcinoma, Transitional Cell; Cisplati | 1984 |
Rationale for intensive intravesical chemotherapy for superficial bladder cancer.
Topics: Animals; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Doxorubicin; Humans; Mito | 1980 |
Treatment of superficial bladder cancer.
Topics: Aged; Antineoplastic Agents; BCG Vaccine; Cystoscopy; Humans; Immunotherapy; Male; Methods; Neoplasm | 1980 |
Chemotherapy of bladder cancer: a review.
Topics: Administration, Topical; Antineoplastic Agents; Clinical Trials as Topic; Doxorubicin; Drug Evaluati | 1981 |
Developing carcinoma (dysplasia) of the urinary bladder.
Topics: Animals; Female; Humans; Male; Microscopy, Electron, Scanning; Precancerous Conditions; Rats; Thiote | 1982 |
[Progress in the internist treatment of bladder tumors].
Topics: Antineoplastic Agents; BCG Vaccine; Cisplatin; Doxorubicin; Ethoglucid; Humans; Leucovorin; Methotre | 1982 |
BCG in perspective: advances in the treatment of superficial bladder cancer.
Topics: Administration, Intravesical; BCG Vaccine; Doxorubicin; Humans; Mitomycin; Neoplasm Recurrence, Loca | 1995 |
Intravesical chemotherapy versus immunotherapy for superficial bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma, | 1996 |
Improved patient outcomes with BCG immunotherapy vs. chemotherapy - Swedish and worldwide experience.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Chemotherapy, Adjuvant; Comb | 2000 |
Intravesical therapy of superficial bladder cancer.
Topics: Administration, Intravesical; Antineoplastic Agents; Doxorubicin; Epirubicin; Humans; Immunotherapy; | 2000 |
An overview of the treatment of superficial bladder cancer. Intravesical chemotherapy.
Topics: Administration, Intravesical; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2000 |
Intravesical therapy for superficial bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Anticarcinogenic | 2000 |
Current therapy of bladder carcinoma.
Topics: Humans; Immunotherapy; Prognosis; Thiotepa; Urinary Bladder; Urinary Bladder Neoplasms | 1979 |
Intravesical and systemic chemotherapy of murine bladder cancer.
Topics: Animals; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Cisplatin; Cyclophosphami | 1977 |
Optimal BCG treatment of superficial bladder cancer as defined by American trials.
Topics: Administration, Intravesical; Administration, Oral; BCG Vaccine; Carcinoma in Situ; Carcinoma, Trans | 1992 |
Adjuvant intravesical therapy for superficial bladder cancer.
Topics: Administration, Intravesical; BCG Vaccine; Chemotherapy, Adjuvant; Clinical Trials as Topic; Doxorub | 1992 |
Managing superficial bladder cancer: an overview.
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Comb | 1992 |
Intravesical chemotherapy. Treatment selection, techniques, and results.
Topics: Administration, Intravesical; Antineoplastic Agents; Carcinoma in Situ; Carcinoma, Transitional Cell | 1992 |
Complications of intravesical chemotherapy.
Topics: Administration, Intravesical; Antineoplastic Agents; Carcinoma, Transitional Cell; Doxorubicin; Epir | 1992 |
Bacillus Calmette-Guérin immunotherapy. Techniques and results.
Topics: Administration, Intravesical; BCG Vaccine; Carcinoma in Situ; Carcinoma, Transitional Cell; Clinical | 1992 |
Current concepts in the management of superficial bladder cancer.
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Combined Modality Therapy; Cystosc | 1990 |
Therapeutic approaches including interferon to carcinoma in situ of the bladder.
Topics: Administration, Topical; BCG Vaccine; Carcinoma in Situ; Cyclophosphamide; Doxorubicin; Ethoglucid; | 1985 |
Rationale for intravesical chemotherapy in the treatment and prophylaxis of superficial transitional cell carcinoma.
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma in Situ; Carcinoma, Tran | 1989 |
BCG versus thiotepa in non-CIS, stage Ta, T1 bladder cancer: rationale and design of ECOG trial.
Topics: Aged; BCG Vaccine; Carcinoma in Situ; Carcinoma, Transitional Cell; Doxorubicin; Female; Humans; Mal | 1989 |
Intravesical chemotherapy: how effective is it?
Topics: Administration, Intravesical; BCG Vaccine; Carcinoma, Transitional Cell; Doxorubicin; Humans; Mitomy | 1988 |
Introduction and overview of intravesical therapy for superficial bladder cancer.
Topics: Administration, Intravesical; BCG Vaccine; Carcinoma in Situ; Carcinoma, Transitional Cell; Doxorubi | 1988 |
Intravesical therapy for bladder cancer.
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Cystoscopy; Doxorubicin; Female; H | 1988 |
The prophylaxis of nonindustrial urothelial tumours.
Topics: Analgesics; Ascorbic Acid; Coffee; Female; Humans; Male; Papilloma; Pyridoxine; Sex Factors; Smoking | 1973 |
Chemotherapy for bladder cancer.
Topics: Administration, Topical; Alkylating Agents; Blood Cell Count; Carcinoma, Papillary; Cystitis; Cystos | 1974 |
48 trials available for thiotepa and Bladder Cancer
| Article | Year |
|---|---|
Intravesical chemotherapy in the United States. An overview.
Topics: BCG Vaccine; Bleomycin; Carcinoma in Situ; Clinical Trials as Topic; Doxorubicin; Humans; Mitomycin; | 1983 |
Influence of thiotepa and doxorubicin instillation at time of transurethral surgical treatment of bladder cancer on tumor recurrence: a prospective, randomized, double-blind, controlled trial.
Topics: Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Doxorubicin; Female; Humans; Male; Middl | 1983 |
Prognostic factors in superficial bladder tumors. A study of the European Organization for Research on Treatment of Cancer: Genitourinary Tract Cancer Cooperative Group.
Topics: Humans; Neoplasm Recurrence, Local; Prognosis; Teniposide; Thiotepa; Urinary Bladder Neoplasms | 1983 |
Long-term fate of 90 patients with superficial bladder cancer randomly assigned to receive or not to receive thiotepa.
Topics: Aged; Carcinoma, Transitional Cell; Female; Follow-Up Studies; Humans; Male; Neoplasm Recurrence, Lo | 1983 |
Bladder cancer chemotherapy studies supported by the National Bladder Cancer Project.
Topics: Adult; Aminoacridines; Amsacrine; Antineoplastic Agents; Carcinoma in Situ; Carcinoma, Papillary; Ci | 1983 |
Cooperative studies of chemoprophylaxis after transurethral resection of bladder tumors.
Topics: Antineoplastic Agents; Carcinoma, Papillary; Cisplatin; Clinical Trials as Topic; Combined Modality | 1983 |
Intravesical chemotherapy for superficial bladder cancer.
Topics: BCG Vaccine; Carcinoma, Transitional Cell; Clinical Trials as Topic; Doxorubicin; Ethoglucid; Follow | 1984 |
Surgery and intravesical chemotherapy in the management of superficial bladder cancer.
Topics: Antineoplastic Agents; BCG Vaccine; Brachytherapy; Carcinoma, Transitional Cell; Clinical Trials as | 1983 |
Treatment of superficial bladder tumors in a controlled trial with thio-TEPA versus adriamycin.
Topics: Administration, Topical; Adult; Aged; Carcinoma, Transitional Cell; Clinical Trials as Topic; Doxoru | 1984 |
Intravesical chemotherapy.
Topics: Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Clinical Trials as Topic; Combined | 1984 |
Intravesical treatment with thiotepa: an update review.
Topics: Carcinoma, Transitional Cell; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Neoplasm | 1984 |
Resume of selected studies of the National Bladder Cancer Collaborative Group A and new protocols.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Cisplatin; Clini | 1984 |
Clinical trials in superficial and invasive bladder cancer.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Clinical Trials as Topic; Combined Modalit | 1984 |
[Adjuvant thio-tepa in the treatment of bladder papilloma. A prospective randomized study].
Topics: Adult; Aged; Electrocoagulation; Female; Humans; Male; Middle Aged; Papilloma; Prospective Studies; | 1980 |
Intravesical chemotherapy in a controlled trial with thio-tepa versus doxorubicin hydrochloride.
Topics: Carcinoma, Transitional Cell; Clinical Trials as Topic; Doxorubicin; Female; Humans; Male; Middle Ag | 1981 |
The effect of thio-TEPA on developing and established mammalian bladder tumors.
Topics: Animals; Clinical Trials as Topic; Female; Mice; Mice, Inbred C3H; Thiotepa; Urinary Bladder Neoplas | 1980 |
Chemotherapy of bladder cancer: a review.
Topics: Administration, Topical; Antineoplastic Agents; Clinical Trials as Topic; Doxorubicin; Drug Evaluati | 1981 |
Prophylactic chemotherapy of superficial transitional cell bladder carcinoma: an EORTC randomized trial comparing thiotepa, an epipodophyllotoxin (VM26) and TUR alone.
Topics: Carcinoma, Transitional Cell; Clinical Trials as Topic; Follow-Up Studies; Humans; Neoplasm Recurren | 1982 |
Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma.
Topics: BCG Vaccine; Carcinoma in Situ; Carcinoma, Transitional Cell; Female; Humans; Male; Middle Aged; Neo | 1982 |
The effect of intravesical thiotepa on tumour recurrence after endoscopic treatment of newly diagnosed superficial bladder cancer. A further report with long-term follow-up of a Medical Research Council randomized trial. Medical Research Council Working P
Topics: Administration, Intravesical; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cystoscopy; Drug | 1994 |
ThioTEPA pharmacokinetics during intravesical chemotherapy: the influence of dose and volume of instillate on systemic uptake and dose rate to the tumour.
Topics: Absorption; Administration, Intravesical; Aged; Analysis of Variance; Antineoplastic Agents, Alkylat | 1996 |
[Prevention of postoperative recurrence of bladder cancer: a clinical study].
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; BCG | 1999 |
Adjuvant therapy of T1 bladder carcinoma: preliminary results of an EORTC randomized study.
Topics: Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Pathology; Podophyllotoxin; Random Allocation; | 1978 |
The role of intravesical thiotepa in the management of superficial bladder cancer. National Bladder Cancer Collaborative Group A.
Topics: Clinical Trials as Topic; Humans; Neoplasm Recurrence, Local; Neoplasms, Multiple Primary; Postopera | 1977 |
Comparisons of placebo, pyridoxine, and topical thiotepa in preventing recurrence of stage I bladder cancer.
Topics: Administration, Oral; Administration, Topical; Clinical Trials as Topic; Drug Evaluation; Follow-Up | 1977 |
Single dose intravesical thiotepa as an adjuvant to cystodiathermy in the treatment of transitional cell bladder carcinoma.
Topics: Carcinoma, Transitional Cell; Clinical Trials as Topic; Electrocoagulation; Female; Follow-Up Studie | 1976 |
The randomized clinical trial: a prerequisite for rational therapy.
Topics: Clinical Trials as Topic; Cyclophosphamide; Diethylstilbestrol; Double-Blind Method; Doxorubicin; Fe | 1976 |
EORTC randomized trial for the adjuvant therapy of T1 bladder carcinoma.
Topics: Carcinoma, Papillary; Clinical Trials as Topic; Follow-Up Studies; Humans; Neoplasm Recurrence, Loca | 1976 |
A prospective randomized study of prophylaxis of tumor recurrence following transurethral resection of superficial bladder cancer--intravesical thio-TEPA versus oral UFT.
Topics: Administration, Intravesical; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Proto | 1992 |
[BCG in superficial carcinoma of the bladder. Authors' experience].
Topics: Administration, Topical; Adult; Aged; BCG Vaccine; Carcinoma in Situ; Drug Evaluation; Female; Human | 1992 |
Adjuvant chemotherapy of recurrent superficial transitional cell carcinoma: results of a European organization for research on treatment of cancer randomized trial comparing intravesical instillation of thiotepa, doxorubicin and cisplatin. The European Or
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Transitiona | 1992 |
ThioTEPA pharmacokinetics during intravesical chemotherapy and the influence of Tween 80.
Topics: Absorption; Administration, Intravesical; Aged; Carcinoma, Transitional Cell; Female; Humans; Hydrog | 1990 |
Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; BCG Vaccine; Carcinoma, Transitional C | 1990 |
Selective chemoprophylaxis guided by multifactorial analysis in superficial bladder cancer.
Topics: Antineoplastic Agents; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Doxorubicin; | 1990 |
Approaches to the treatment of bladder cancer at Stanford.
Topics: Administration, Intravesical; Antineoplastic Agents; Carcinoma in Situ; Carcinoma, Papillary; Carcin | 1987 |
Prognostic factors for recurrence and followup policies in the treatment of superficial bladder cancer: report from the British Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party).
Topics: Administration, Intravesical; Carcinoma, Transitional Cell; Cystoscopy; Follow-Up Studies; Humans; M | 1989 |
Intravesical therapy comparing BCG, adriamycin, and thiotepa in 200 patients with superficial bladder cancer: a randomized prospective study.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; BCG Vaccine; Carcinoma, Transitional C | 1989 |
BCG versus thiotepa in non-CIS, stage Ta, T1 bladder cancer: rationale and design of ECOG trial.
Topics: Aged; BCG Vaccine; Carcinoma in Situ; Carcinoma, Transitional Cell; Doxorubicin; Female; Humans; Mal | 1989 |
The effect of intravesical thiotepa on the recurrence rate of newly diagnosed superficial bladder cancer. An MRC Study. MRC Working Party on Urological Cancer.
Topics: Adult; Aged; Carcinoma, Transitional Cell; Clinical Trials as Topic; Cystoscopy; Humans; Middle Aged | 1985 |
Combination intraventricular chemotherapy for meningeal neoplasia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cytarabi | 1986 |
Review of Mayo Clinic experience with carcinoma in situ.
Topics: Carcinoma in Situ; Clinical Trials as Topic; Humans; Mitomycins; Random Allocation; Thiotepa; Urinar | 1986 |
A trial of prophylactic thiotepa or mitomycin C intravesical therapy in patients with recurrent or multiple superficial bladder cancers.
Topics: Carcinoma, Transitional Cell; Clinical Trials as Topic; Humans; Mitomycin; Mitomycins; Neoplasm Recu | 1986 |
Crossed chemoprophylaxis assay between adriamycin and cis-platinum in recurrent superficial bladder tumor.
Topics: Cisplatin; Doxorubicin; Humans; Neoplasm Recurrence, Local; Random Allocation; Thiotepa; Urinary Bla | 1986 |
Prophylactic treatment for superficial bladder cancer following transurethral resection.
Topics: Administration, Intravesical; Aged; Antineoplastic Agents; Carcinoma, Transitional Cell; Combined Mo | 1987 |
Intravesical thiotepa versus mitomycin C in patients with Ta, T1 and TIS transitional cell carcinoma of the bladder: a phase III prospective randomized study.
Topics: Administration, Intravesical; Carcinoma, Transitional Cell; Clinical Trials as Topic; Humans; Mitomy | 1988 |
First-line chemotherapy of superficial bladder cancer: mitomycin vs thiotepa.
Topics: Carcinoma, Transitional Cell; Clinical Trials as Topic; Drug Evaluation; Humans; Mitomycins; Neoplas | 1985 |
Mitomycin for patients who have failed on thiotepa. The National Bladder Cancer Group.
Topics: Administration, Topical; Biopsy; Carcinoma in Situ; Clinical Trials as Topic; Cystitis; Cystoscopy; | 1985 |
Intravesical thiotepa and mitomycin C treatment immediately after transurethral resection and later for superficial (stages Ta and Tis) bladder cancer: a prospective, randomized, stratified study with crossover design.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Carcinoma in Situ; Carcinoma, Transitional Cell; Clinical | 1985 |
234 other studies available for thiotepa and Bladder Cancer
| Article | Year |
|---|---|
Single-dose perioperative mitomycin-C versus thiotepa for low-grade noninvasive bladder cancer.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic A | 2019 |
Case-cohort analysis of clusters of recurrent events.
Topics: Cluster Analysis; Cohort Studies; Computer Simulation; Humans; Likelihood Functions; Neoplasm Recurr | 2014 |
Modeling zero-inflated count data when exposure varies: With an application to tumor counts.
Topics: Biometry; Follow-Up Studies; Humans; Models, Statistical; Poisson Distribution; Randomized Controlle | 2013 |
Sieve estimation in semiparametric modeling of longitudinal data with informative observation times.
Topics: Aged; Computer Simulation; Female; Heart Failure; Humans; Least-Squares Analysis; Longitudinal Studi | 2014 |
Regression modeling of longitudinal data with outcome-dependent observation times: extensions and comparative evaluation.
Topics: Antineoplastic Agents, Alkylating; Bias; Biometry; Computer Simulation; Data Interpretation, Statist | 2014 |
Whither thiotepa (for patients in the USA)?
Topics: Antineoplastic Agents, Alkylating; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Th | 2015 |
Multiple outputation for the analysis of longitudinal data subject to irregular observation.
Topics: Antineoplastic Agents, Alkylating; Bayes Theorem; Child; Computer Simulation; Dermatomyositis; Human | 2016 |
Intravesical chemotherapy use after radical nephroureterectomy: A national survey of urologic oncologists.
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Chem | 2017 |
Empirical receiver operating characteristic curve for two-sample comparison with cure fractions.
Topics: Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Computer Simulation; Humans; Models, St | 2010 |
Saddlepoint p-values and confidence intervals for a class of two sample permutation tests for current status and panel count data.
Topics: Animals; Antineoplastic Agents, Alkylating; Biometry; Computer Simulation; Confidence Intervals; Dat | 2011 |
32p-labeled thio-tepa absorption in normal rat bladders: potential guide for intravesical chemotherapy in bladder cancer.
Topics: Absorption; Administration, Intravesical; Animals; Female; Phosphorus Radioisotopes; Rats; Rats, Inb | 1974 |
Weighted logrank tests for interval censored data when assessment times depend on treatment.
Topics: Antineoplastic Agents, Alkylating; Bias; Biometry; Cluster Analysis; Computer Simulation; Data Inter | 2012 |
Thiotepa in the treatment of tumours of the bladder.
Topics: Antineoplastic Agents; Humans; Neoplasms; Thiotepa; Urinary Bladder Neoplasms | 1961 |
Bladder carcinoma treated by direct instillation of thio-TEPA.
Topics: Antineoplastic Agents; Humans; Thiotepa; Urinary Bladder Neoplasms | 1962 |
THE TOPICAL USE OF CYTOTOXIC DRUGS FOR BLADDER CANCER.
Topics: Antineoplastic Agents; Carcinoma; Carcinoma, Papillary; Humans; Thiotepa; Urinary Bladder Neoplasms; | 1963 |
[TREATMENT OF CANCER OF THE BLADDER].
Topics: Cystoscopy; Mechlorethamine; Neoplasms; Pathology; Surgical Procedures, Operative; Thiotepa; Urinary | 1963 |
[STUDY OF VARIATIONS IN THE COMPLEMENT LEVEL IN THE COURSE OF CANCER CHEMOTHERAPY].
Topics: Animals; Breast Neoplasms; Bronchial Neoplasms; Complement System Proteins; Cyclophosphamide; Dexame | 1964 |
[THE PRACTITIONER AND ANTINEOPLASTIC CHEMOTHERAPY. RECENT DATA].
Topics: Antineoplastic Agents; Dactinomycin; Glioma; Hodgkin Disease; Leukemia; Leukemia, Myeloid; Perfusion | 1965 |
TREATMENT OF BLADDER TUMORS BY INSTILLATION OF THIO-TEPA, ACTINOMYCIN D, OR 5-FLUOROURACIL.
Topics: Carcinoma; Carcinoma, Papillary; Dactinomycin; Drug Therapy; Fluorouracil; Humans; Neoplasms; Thiote | 1965 |
[TREATMENT OF BLADDER NEOPLASMS BY MEANS OF RADIOACTIVE NITROGEN MUSTARD].
Topics: Humans; Mechlorethamine; Sulfur Isotopes; Thiotepa; Urinary Bladder Neoplasms | 1965 |
THE TREATMENT OF ADVANCED CARCINOMA OF THE BLADDER.
Topics: Antimetabolites; Carcinoma; Cobalt Isotopes; Cyclophosphamide; Humans; Neoplasms; Palliative Care; P | 1965 |
Adjuvant therapy in different risk-groups of patients with superficial bladder cancer.
Topics: Adjuvants, Immunologic; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; BCG Va | 2005 |
A chemosensitivity test for superficial bladder cancer based on three-dimensional culture of tumour spheroids.
Topics: Antineoplastic Agents; Ciprofloxacin; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, | 2007 |
In vitro chemotherapy testing of transitional cell carcinoma.
Topics: Antineoplastic Agents; Bleomycin; Carcinoma, Transitional Cell; Cells, Cultured; Cisplatin; Cyclopho | 1980 |
In vitro chemosensitivity of human bladder cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Carcinoma, Transitional Cell; Cell Survival; Cel | 1983 |
[Chemosensitivity in established human bladder carcinoma and HELA cell lines in vitro].
Topics: Antineoplastic Agents; Bleomycin; Carbazilquinone; Carcinoma, Transitional Cell; Cell Division; Cell | 1983 |
[Intravesical chemotherapy for superficial bladder tumors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carbazilquinone; Cytarabine; Doxorubicin; | 1984 |
A comparison of treatment methods for the prophylaxis of recurrent superficial bladder tumors.
Topics: Administration, Oral; Administration, Topical; Adult; Aged; BCG Vaccine; Carcinoma, Transitional Cel | 1983 |
Bladder cancer. Management of an increasingly common tumor.
Topics: Endoscopy; Humans; Neoplasm Recurrence, Local; Thiotepa; Urinary Bladder Neoplasms | 1983 |
Interaction of ultrasonic hyperthermia with two alkylating agents in a murine bladder tumor.
Topics: Animals; Cyclophosphamide; DNA; Female; Hot Temperature; Mitotic Index; Neoplasm Transplantation; Ne | 1983 |
[Use of thiotepa, in local instillation, as a prophylactic treatment for recurrence of superficial tumors of the bladder].
Topics: Administration, Topical; Adult; Aged; Carcinoma, Transitional Cell; Female; Humans; Male; Middle Age | 1983 |
[Bladder cancer].
Topics: Humans; Infusions, Intra-Arterial; Thiotepa; Urinary Bladder Neoplasms | 1983 |
Intravesical thiotepa prophylaxis of superficial bladder cancer. A follow-up study.
Topics: Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Invasiv | 1983 |
Acute nonlymphocytic leukemia following bladder instillations with thiotepa.
Topics: Acute Disease; Aged; Humans; Leukemia; Male; Papilloma; Thiotepa; Time Factors; Urinary Bladder; Uri | 1983 |
The influence of lower urinary tract infection on the recurrence rate of superficial transitional cell carcinoma of the bladder.
Topics: Aged; Animals; Anti-Bacterial Agents; Carcinoma, Transitional Cell; Cystitis; Dogs; Female; Humans; | 1983 |
Thiotepa-induced myelosuppression: review of 670 bladder instillations.
Topics: Adult; Aged; Female; Humans; Leukopenia; Male; Middle Aged; Thiotepa; Thrombocytopenia; Urinary Blad | 1983 |
Comparison of the efficacy of intravesical Bacillus Calmette-Guérin with thiotepa, mitomycin C, poly I:C/poly-L-lysine and cis platinum in murine bladder cancer.
Topics: Administration, Topical; Animals; Antineoplastic Agents; BCG Vaccine; Cisplatin; Female; Mice; Mice, | 1984 |
Does intravesical chemotherapy prevent invasive bladder cancer?
Topics: Administration, Topical; Aged; Antineoplastic Agents; Carcinoma, Transitional Cell; Follow-Up Studie | 1984 |
Mitomycin C intravesical therapy in noninvasive bladder cancer after failure on thiotepa.
Topics: Adult; Aged; Drug Evaluation; Humans; Inflammation; Middle Aged; Mitomycin; Mitomycins; Skin Disease | 1984 |
[Transitory effect of thiotepa on spermatogenesis].
Topics: Humans; Male; Spermatogenesis; Thiotepa; Urinary Bladder Neoplasms | 1983 |
Verapamil enhancement of chemotherapeutic efficacy in human bladder cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cell Division; Cell Li | 1984 |
Enhanced lethality by methylxanthines in human bladder cancer cells treated with thiotepa.
Topics: Antineoplastic Combined Chemotherapy Protocols; Caffeine; Carcinoma, Transitional Cell; Cell Divisio | 1984 |
Further comments on 1744 bladder tumors.
Topics: Cobalt Radioisotopes; Combined Modality Therapy; Doxorubicin; Humans; Neoplasm Staging; Thiotepa; Ur | 1984 |
Management of superficial bladder carcinoma with BCG. Long term follow-up.
Topics: BCG Vaccine; Combined Modality Therapy; Follow-Up Studies; Humans; Neoplasm Recurrence, Local; Thiot | 1984 |
Choosing the right intravesical chemotherapeutic agent. Results of an in vitro monolayer cell culture assay.
Topics: Antibiotics, Antineoplastic; Cell Survival; Cells, Cultured; Doxorubicin; Humans; Mitomycin; Mitomyc | 1984 |
The value of thiotepa in the treatment of superficial bladder tumors.
Topics: Adult; Aged; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neopla | 1984 |
Studies of the morphological effects of thiotepa and adriamycin on urothelium.
Topics: Animals; Doxorubicin; Epithelium; Female; Rats; Thiotepa; Urinary Bladder; Urinary Bladder Neoplasms | 1984 |
The effects of intravesical instillation of Thio-Tepa on the recurrence rate of bladder tumors.
Topics: Adolescent; Adult; Aged; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Thiotepa | 1980 |
The effect of chemotherapeutic agents on the ultrastructure of transitional cell carcinoma in tissue culture.
Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Cell Nucleolus; Fluorouracil; Humans; In Vitro | 1980 |
Effects of therapy on carcinoembryonic antigen activity in the urines of patients with cancer of the bladder.
Topics: Carcinoembryonic Antigen; Carcinoma, Transitional Cell; Humans; Neoplasm Staging; Thiotepa; Urinary | 1980 |
The management of superficial bladder cancer.
Topics: Adenocarcinoma; Carcinoma, Papillary; Carcinoma, Transitional Cell; Humans; Methods; Mitomycins; Neo | 1980 |
[The recurrence after conservative therapy of bladder cancer. II: The intravesical instillation of anti-cancer drug for preventing recurrence (author's transl)].
Topics: Adolescent; Adult; Aged; Chemotherapy, Cancer, Regional Perfusion; Child; Female; Humans; Male; Midd | 1980 |
Rapid assay system for cytotoxicity tests using 14C-leucine incorporation into tumor cells.
Topics: Antineoplastic Agents; Carbon Radioisotopes; Carcinoma, Transitional Cell; Cell Line; Cell Survival; | 1980 |
Hematologic effects of intravesicular thiotepa therapy for bladder carcinoma.
Topics: Adult; Aged; Anemia; Blood Cell Count; Bone Marrow; Female; Hematologic Diseases; Humans; Injections | 1980 |
[Depression of bone marrow after intravesical use of Thio-tepa].
Topics: Aged; Bone Marrow; Female; Humans; Papilloma; Thiotepa; Urinary Bladder Neoplasms | 1980 |
The use of intravesical thio-tepa in the management of non-invasive carcinoma of the bladder.
Topics: Humans; Neoplasm Recurrence, Local; Remission, Spontaneous; Thiotepa; Urinary Bladder; Urinary Bladd | 1981 |
[Reoperation for severe hematuria following chemotherapy for bladder papillomatosis previously treated by surgery and cobalt therapy].
Topics: Administration, Topical; Aged; Hematuria; Humans; Male; Neoplasm Recurrence, Local; Papilloma; Thiot | 1981 |
[Bladder tumors].
Topics: Carcinoma in Situ; Cystitis; Diagnosis, Differential; Doxorubicin; Humans; Thiotepa; Urinary Bladder | 1981 |
Intravesical thiotepa in prevention of recurrence of bladder tumour.
Topics: Adult; Female; Humans; Male; Neoplasm Recurrence, Local; Thiotepa; Urinary Bladder; Urinary Bladder | 1980 |
The morphologic effects of mitomycin C in mammalian urinary bladder.
Topics: Administration, Topical; Animals; FANFT; Female; Mice; Mice, Inbred C3H; Mitomycins; Necrosis; Neopl | 1981 |
Pathological changes associated with topical chemotherapy for superficial bladder cancer.
Topics: Administration, Topical; Aged; Carcinoma; Dose-Response Relationship, Drug; Drug Therapy, Combinatio | 1981 |
Cancer of the bladder; a case history.
Topics: Aged; Carcinoma, Transitional Cell; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Stagi | 1981 |
Use of intravesical thiotepa in superficial bladder tumours.
Topics: Administration, Topical; Female; Follow-Up Studies; Humans; Male; Neoplasm Recurrence, Local; Neopla | 1981 |
Early multiple-dose adjuvant thiotepa in the control of multiple and rapid T1 tumour neogenesis.
Topics: Drug Administration Schedule; Electrocoagulation; Female; Humans; Male; Middle Aged; Neoplasm Recurr | 1981 |
Single and sequential combination intravesical chemotherapy of murine bladder cancer.
Topics: Animals; Antineoplastic Agents; Cisplatin; Disease Models, Animal; Doxorubicin; Drug Therapy, Combin | 1982 |
Sterilisation following instillation of thiotepa into the urinary bladder.
Topics: Adult; Carcinoma, Transitional Cell; Humans; Infertility, Male; Male; Thiotepa; Urinary Bladder Neop | 1982 |
Unanticipated vesicoureteral reflux: a possible sequela of long-term thio-tepa instillations to the bladder.
Topics: Carcinoma, Transitional Cell; Female; Humans; Male; Mucous Membrane; Thiotepa; Urethra; Urinary Blad | 1982 |
Intravesical therapy of low stage bladder carcinoma with mitomycin C: comparison of results in untreated and previously treated patients.
Topics: Adult; Aged; Carcinoma in Situ; Carcinoma, Transitional Cell; Drug Resistance; Female; Humans; Male; | 1982 |
Early onset life-threatening myelosuppression after low dose of intravesical thiotepa.
Topics: Aged; Carcinoma, Papillary; Humans; Male; Pancytopenia; Thiotepa; Urinary Bladder Neoplasms | 1982 |
[Possibilities and value of intracavitary and systemic chemotherapy of bladder cancer].
Topics: Antineoplastic Agents; Carcinoma in Situ; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Therapy, Co | 1982 |
Poisson regression analysis in clinical research.
Topics: Epilepsy; Humans; Mathematical Computing; Models, Biological; Placebos; Poisson Distribution; Pyrido | 1995 |
Rapid tumour recurrence following cessation of long-term treatment with intravesical thiotepa.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; BCG Vaccine; Carcinoma, Transitional Cell; Fe | 1994 |
[Tumors of the superior urinary tract and associated bladder tumors: clinical and etiological aspects].
Topics: Aged; Aged, 80 and over; Combined Modality Therapy; Cystectomy; Female; Follow-Up Studies; Humans; I | 1993 |
Effect of different local and systemic therapy upon urinary bladder cytology.
Topics: Administration, Intravesical; Aged; Carcinoma, Transitional Cell; Combined Modality Therapy; DNA, Ne | 1993 |
Nonparametric analysis of recurrent events and death.
Topics: Antineoplastic Agents, Alkylating; Biometry; Cause of Death; Controlled Clinical Trials as Topic; Hu | 2000 |
A general family of distributions for longitudinal dependence with special reference to event histories.
Topics: Antineoplastic Agents, Alkylating; Granulomatous Disease, Chronic; Humans; Interferon-gamma; Longitu | 2001 |
[Treatment of bladder tumors].
Topics: Ethoglucid; Humans; Palliative Care; Thiotepa; Urinary Bladder Neoplasms | 1976 |
[Late results of the combined treatment of bladder cancer depending on the histological form of the tumor].
Topics: Adult; Aged; Cyclophosphamide; Female; Humans; Male; Middle Aged; Neoplasm Staging; Palliative Care; | 1978 |
Chemotherapy in bladder carcinoma.
Topics: Antineoplastic Agents; Bleomycin; Doxorubicin; Drug Therapy, Combination; Fluorouracil; Humans; Recu | 1978 |
[Serious complications following topical administration of thio-tepa in a patient with bladder carcinoma].
Topics: Administration, Topical; Carcinoma; Humans; Male; Pyelonephritis; Thiotepa; Urinary Bladder Neoplasm | 1978 |
Changes of cell cycle affecting cidal effect of triethylene thiophosphoramide on cultured human bladder carcinoma cells.
Topics: Cell Cycle; Cell Line; Humans; Thiotepa; Time Factors; Urinary Bladder Neoplasms | 1978 |
Intravesical thio-tepa in the immediate postoperative period in patients with recurrent transitional cell carcinoma of the bladder.
Topics: Adolescent; Adult; Aged; Animals; Carcinoma, Transitional Cell; Child; Child, Preschool; Dogs; Follo | 1978 |
Chemotherapy of bladder tumours.
Topics: Antineoplastic Agents; Carcinoma in Situ; Carcinoma, Papillary; Humans; Neoplasm Metastasis; Papillo | 1978 |
[Enhanced cell killing by thio-TEPA and urokinase (author's transl)].
Topics: Cell Division; Cell Survival; Cells, Cultured; Drug Synergism; Drug Therapy, Combination; Endopeptid | 1979 |
Intravesical thio-tepa: a study of 3H-thymidine uptake in normal urothelium and FANFT-induced tumors in rats.
Topics: Animals; Autoradiography; Carcinoma, Transitional Cell; DNA, Neoplasm; Epithelium; FANFT; Female; Ne | 1979 |
A longitudinal study of patients with superficial bladder carcinoma successfully treated with weekly intravesical thio-tepa.
Topics: Carcinoma, Transitional Cell; Female; Humans; Longitudinal Studies; Male; Thiotepa; Urinary Bladder | 1979 |
Local application of THIO-TEPA in the prevention of recurrent papillary carcinoma of the bladder.
Topics: Administration, Topical; Adult; Aged; Carcinoma, Papillary; Female; Humans; Male; Middle Aged; Neopl | 1979 |
Intravesical chemotherapy and chemoprevention of superficial, low grade, low stage bladder carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Humans; Neoplasm Recurrence, Local; Thiotepa; T | 1979 |
[Round-table: Chemotherapy of bladder tumors].
Topics: Animals; Drug Therapy, Combination; Humans; Neoplasms, Experimental; Papilloma; Thiotepa; Urinary Bl | 1979 |
The chemotherapy of urologic cancer.
Topics: Adenocarcinoma; Adult; Aged; Alkylating Agents; Antineoplastic Agents; Doxorubicin; Drug Therapy, Co | 1975 |
[Local administration of thio-tepa in the prevention of papillomatous neoplasms of the urinary bladder].
Topics: Administration, Topical; Adult; Aged; Female; Humans; Male; Methods; Middle Aged; Papilloma; Thiotep | 1977 |
[Hyperthermic treatment for the bladder tumor (II) (author's transl)].
Topics: Adult; Aged; Doxorubicin; Female; Hot Temperature; Humans; Male; Middle Aged; Thiotepa; Urinary Blad | 1977 |
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 28-1977.
Topics: Aged; Carcinoma, Transitional Cell; Diagnosis, Differential; Female; Humans; Leukemia, Myeloid, Acut | 1977 |
Cidal and subcidal effect of triethylene thiophosphoramide on cell kinetics of human bladder carcinoma cells in vitro.
Topics: Cell Division; Cell Survival; Humans; In Vitro Techniques; Thiotepa; Urinary Bladder Neoplasms | 1977 |
Clinical observations on sixty-nine cases of in situ carcinoma of the urinary bladder.
Topics: Adult; Aged; Anaplasia; Carcinoma in Situ; Carcinoma, Transitional Cell; Cystoscopy; Female; Humans; | 1977 |
[Thio-Tepa in the chemotherapy and chemical prevention of papillary neoplasms of the bladder].
Topics: Carcinoma, Papillary; Humans; Thiotepa; Urinary Bladder Neoplasms | 1977 |
[Chemotherapy of bladder neoplasms--studies of preventive measures against recurrence of superficial bladder neoplasms].
Topics: Carcinoma, Transitional Cell; Female; Humans; Male; Mitomycins; Neoplasm Recurrence, Local; Thiotepa | 1977 |
[Own experiences with the treatment of papillomatous bladder neoplasms by intracystic administration of Thio-Tepa].
Topics: Adult; Aged; Female; Humans; Male; Methods; Middle Aged; Papilloma; Thiotepa; Urinary Bladder; Urina | 1977 |
Treatment of Condyloma acuminata in male patients.
Topics: Adult; Condylomata Acuminata; Electrocoagulation; Ethoglucid; Humans; Immunotherapy; Male; Thiotepa; | 1977 |
[Endoscopic resection in the treatment of non-invasive excreto-urinary carcinomas of the bladder 146 endoscopic resections carried out in 53 patients].
Topics: Adult; Aged; Animals; Carcinoma, Papillary; Endoscopy; Female; Humans; Male; Middle Aged; Neoplasm R | 1977 |
The prophylactic use of Thio-TEPA, an adjuvant in the treatment of bladder tumours.
Topics: Humans; Recurrence; Thiotepa; Urinary Bladder Neoplasms | 1977 |
The effect of intravesical thio-tepa on normal and tumor urothelium.
Topics: Carcinoma, Transitional Cell; Epithelium; Humans; Recurrence; Thiotepa; Urinary Bladder; Urinary Bla | 1978 |
[Cell kinetics of the bladder carcinoma. III. Changes of the cell cycle following thio-TEPA treatment and possible factors for kinetics of cell killing in cultured human bladder carcinoma cells (author's transl)].
Topics: Cell Cycle; Cell Division; Cell Survival; Cells, Cultured; Humans; Kinetics; Thiotepa; Urinary Bladd | 1977 |
[The harmfulness of intravesical instillations of thiotepa in cases of vesico-renal reflux].
Topics: Aged; Carcinoma, Transitional Cell; Humans; Leukopenia; Male; Thiotepa; Thrombocytopenia; Urinary Bl | 1978 |
Proceedings: Adjuvant intravesical thiotepa and bladder tumour recurrence.
Topics: Humans; Neoplasm Recurrence, Local; Neoplasm Seeding; Thiotepa; Urinary Bladder Neoplasms | 1975 |
The prophylactic use of thio-tepa and urokinase in transitional cell carcinoma of the bladder: a preliminary report.
Topics: Adolescent; Adult; Aged; Carcinoma, Transitional Cell; Cystitis; Drug Therapy, Combination; Endopept | 1975 |
Permeability of normal and cancerous rat bladder to antineoplastic agents.
Topics: Animals; Antineoplastic Agents; Epithelium; FANFT; Female; Leukocyte Count; Neoplasms, Experimental; | 1975 |
Prophylaxis of bladder tumor implantation. Intravesical and systemic chemotherapy.
Topics: Animals; Antineoplastic Agents; Carcinoma, Transitional Cell; Disease Models, Animal; Doxorubicin; F | 1976 |
Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors.
Topics: Aged; BCG Vaccine; Carcinoma, Transitional Cell; Female; Humans; Hypersensitivity, Delayed; Immunoth | 1976 |
Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors.
Topics: Aged; BCG Vaccine; Carcinoma, Transitional Cell; Female; Humans; Hypersensitivity, Delayed; Immunoth | 1976 |
Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors.
Topics: Aged; BCG Vaccine; Carcinoma, Transitional Cell; Female; Humans; Hypersensitivity, Delayed; Immunoth | 1976 |
Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors.
Topics: Aged; BCG Vaccine; Carcinoma, Transitional Cell; Female; Humans; Hypersensitivity, Delayed; Immunoth | 1976 |
Absorption of drugs from the bladder and intravesical chemotherapy.
Topics: Animals; Antineoplastic Agents; Humans; Injections, Intravenous; Pharmaceutical Preparations; Rabbit | 1976 |
[Cell kinetics of the bladder carcinoma. II. Effects of thio-TEPA on proliferative kinetics of the cultured human bladder carcinoma cells (author's transl)].
Topics: Carcinoma, Transitional Cell; Cell Line; Humans; In Vitro Techniques; Kinetics; Mitosis; Thiotepa; U | 1976 |
Vesicoureteral reflux in recurrent carcinoma of the bladder--implications for treatment and prognosis.
Topics: Adult; Aged; Carcinoma, Transitional Cell; Female; Humans; Male; Middle Aged; Prognosis; Recurrence; | 1976 |
[Intravesical BCG, mitomycin-C and thiotepa in the prevention of bladder tumor recurrence after operation].
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Chem | 1992 |
Superficial bladder disease: case studies and therapeutic advances.
Topics: Administration, Intravesical; Adult; Aged; Antineoplastic Agents; BCG Vaccine; Carcinoma in Situ; Ca | 1992 |
Effects of photodynamic therapy in combination with intravesical drugs in a murine bladder tumor model.
Topics: Administration, Intravesical; Animals; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; | 1992 |
Recurrence and treatment of urinary bladder cancer after failure in radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Doxorubicin; Female; Humans; Male; Middle | 1990 |
[Superficial bladder cancer: prophylaxis of recurrence and progression].
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Bleomycin; Cisplatin; Doxorubicin; | 1991 |
The effect of pH on the in vitro colony forming ability of transitional cell carcinoma cells treated with various chemotherapeutic agents: implications for in vivo therapy.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Transitional Cell; Doxorubicin; Humans; Hydrogen-Ion | 1992 |
Intravesical chemotherapy for superficial carcinoma of the bladder.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Carcinoma, Transitional Cell; Female; | 1991 |
Superficial bladder cancer: survival and prognostic factors.
Topics: Administration, Intravesical; Adolescent; Adult; Aged; BCG Vaccine; Carcinoma in Situ; Carcinoma, Sq | 1991 |
In vitro study of the interaction of doxorubicin, thiotepa, and mitomycin-C, agents used for intravesical chemotherapy of superficial bladder cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; | 1991 |
Nephrogenic adenoma in a patient with chronic renal failure associated with intravesical treatment with thiotepa.
Topics: Adenoma; Administration, Intravesical; Carcinoma, Transitional Cell; Humans; Kidney Failure, Chronic | 1990 |
Superficial bladder cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carcinoma, Papillary; Doxorubici | 1985 |
Treatment of patients with transitional cell carcinoma of the urinary bladder with intravesical poly I: poly C effects on natural killer function.
Topics: Adult; Aged; Carcinoma, Transitional Cell; Cytotoxicity, Immunologic; Humans; Immunity, Innate; Immu | 1985 |
Effects of interferon in combination with cytotoxic drugs on mouse bladder tumor (MBT-2) growth in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Dose-Response Relationship, Drug; Doxorubicin; Drug Therapy, Combina | 1988 |
Combined intracavitary and external beam irradiation for superficial transitional cell carcinoma of the bladder: an alternative to cystectomy for patients with recurrence after intravesical chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Transitional Cell; C | 1989 |
Sensitivities of monolayers and spheroids of the human bladder cancer cell line MGH-U1 to the drugs used for intravesical chemotherapy.
Topics: Administration, Topical; Bromodeoxyuridine; Carcinoma, Transitional Cell; Cell Survival; DNA, Neopla | 1989 |
Treatment modalities in superficial bladder cancer.
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Doxo | 1989 |
The effect of liposome encapsulated antineoplastic agents on transitional cell carcinoma in tissue culture.
Topics: Administration, Intravesical; Carcinoma, Transitional Cell; Cisplatin; Dose-Response Relationship, D | 1989 |
Conservative treatment of diffuse carcinoma in situ of the bladder with repeated courses of intravesical therapy.
Topics: Administration, Intravesical; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Car | 1989 |
Inhibition of implantation of murine bladder tumor by thiotepa in cauterized bladder.
Topics: Administration, Intravesical; Animals; Carcinoma, Transitional Cell; Cautery; Disease Models, Animal | 1989 |
Intravesical chemotherapy.
Topics: Administration, Topical; Humans; Thiotepa; Time Factors; Urinary Bladder; Urinary Bladder Neoplasms | 1986 |
Transitional explant reduction assay--a new in vitro testing system for intravesical chemotherapy.
Topics: Carcinoma, Transitional Cell; Cisplatin; Colony-Forming Units Assay; Doxorubicin; Drug Evaluation; D | 1986 |
Use of intravesical cisplatin and mitomycin-C for recurrent transitional cell carcinoma of bladder refractory to thiotepa.
Topics: Biopsy; Carcinoma in Situ; Carcinoma, Transitional Cell; Cisplatin; Cystoscopy; Drug Evaluation; Dru | 1986 |
Cytotoxic, cell cycle, and chromosomal effects of methylxanthines in human tumor cells treated with alkylating agents.
Topics: Alkylating Agents; Caffeine; Cell Cycle; Cell Line; Cell Survival; Chromosome Aberrations; Chromosom | 1986 |
Intravesical chemotherapy: studies on the relationship between osmolality and cytotoxicity.
Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Cell Line; Cisplatin; Colony-Forming Units Assa | 1986 |
Intravesical chemotherapy. Studies on the relationship between pH and cytotoxicity.
Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Cell Line; Cisplatin; Doxorubicin; Epirubicin; | 1986 |
Intravesical chemotherapy: in vitro studies on the relationship between dose and cytotoxicity.
Topics: Antineoplastic Agents; Cell Line; Cell Survival; Dose-Response Relationship, Drug; Doxorubicin; Etho | 1986 |
[Pathomorphosis of bladder cancer after endolymphatic polychemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Cancer, | 1986 |
[Pre-operative one-shot intra-arterial infusion chemotherapy of bladder cancer. 1. Experimental studies on the selection of drugs].
Topics: Animals; Cisplatin; Dogs; Doxorubicin; Infusions, Intra-Arterial; Preoperative Care; Thiotepa; Tissu | 1986 |
Verapamil enhanced in vitro chemosensitivity of a murine bladder carcinoma, FCB.
Topics: Animals; Carcinoma, Transitional Cell; Cell Division; Cells, Cultured; Dose-Response Relationship, D | 1986 |
[Chemoprophylaxis with intravesical thiotepa in non-infiltrating bladder tumors].
Topics: Administration, Intravesical; Adult; Aged; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, L | 1986 |
[Intravesical application of thio-tepa for preventing postoperative recurrence of bladder carcinoma].
Topics: Administration, Intravesical; Carcinoma, Squamous Cell; Humans; Neoplasm Recurrence, Local; Postoper | 1986 |
Distilled water versus chemotherapeutic agents for transitional bladder carcinoma.
Topics: Carcinoma, Transitional Cell; Cell Survival; Humans; In Vitro Techniques; Mitomycin; Mitomycins; Neo | 1986 |
[Vesicorenal reflux following endoscopic treatment of vesical tumors. Developmental and therapeutic complications].
Topics: Aged; Carcinoma, Papillary; Cystoscopy; Humans; Kidney Diseases; Male; Middle Aged; Neoplasm Recurre | 1986 |
Intravesical chemotherapy: combination with Tween 80 increases cytotoxicity in vitro.
Topics: Administration, Intravesical; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Colony- | 1987 |
Bacillus Calmette-Guerin for treatment of superficial transitional cell carcinoma of the bladder in patients who have failed thiotepa and/or mitomycin C.
Topics: Administration, Intravesical; BCG Vaccine; Carcinoma in Situ; Carcinoma, Transitional Cell; Female; | 1987 |
In vitro drug sensitivity studies in human transitional cell carcinoma of the bladder.
Topics: Carcinoma, Transitional Cell; Clone Cells; Colony-Forming Units Assay; Culture Techniques; Dimethyl | 1987 |
Selecting initial therapy for bladder cancer.
Topics: Administration, Intravesical; BCG Vaccine; Combined Modality Therapy; Cystoscopy; Doxorubicin; Human | 1987 |
Factors influencing the absorption of antineoplastic agents in intravesical instillation treatment of bladder tumors. An experimental and clinical study.
Topics: Absorption; Administration, Intravesical; Adult; Aged; Animals; Camptothecin; Carcinoma, Transitiona | 1987 |
Generalized hypersensitivity reaction to intravesical thiotepa and doxorubicin.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Carcinoma, Transitional Cell; Doxorubicin; Dr | 1987 |
Acute nonlymphocytic leukemia after thiotepa instillation into the bladder: report of 2 cases and review of the literature.
Topics: Administration, Intravesical; Aged; Carcinoma, Papillary; Carcinoma, Transitional Cell; Humans; Leuk | 1987 |
[Prognostic factors and risk of recurrence in a series of 385 patients with superficial bladder carcinoma treated with thiotepa, adriamycin or cisplatin].
Topics: Antineoplastic Agents; Cisplatin; Doxorubicin; Female; Humans; Male; Neoplasm Recurrence, Local; Pro | 1987 |
[Conservative treatment of bladder epitheliomas by partial cystectomy and iridium-192 curietherapy].
Topics: Adult; Aged; Brachytherapy; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Humans; Iri | 1987 |
Preoperative one-shot intra-arterial infusion chemotherapy for bladder cancer.
Topics: Animals; Antineoplastic Agents; Cisplatin; Dogs; Doxorubicin; Female; Humans; Iliac Artery; Infusion | 1987 |
5-year experience with intravesical therapy of carcinoma in situ: an inquiry into the risks of "conservative" management.
Topics: Administration, Intravesical; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carcinoma | 1987 |
Bladder wall calcification after topical mitomycin C.
Topics: Administration, Intravesical; Aged; Calcinosis; Carcinoma, Transitional Cell; Combined Modality Ther | 1987 |
[Preventive value of intravesical thiotepa on the recurrence of Ta-T1 vesical tumors treated by conservative surgery. Apropos of 247 cases a mean follow-up of 88 months].
Topics: Administration, Intravesical; Combined Modality Therapy; Follow-Up Studies; Humans; Neoplasm Recurre | 1987 |
Intractable bladder hemorrhage requiring cystectomy after use of intravesical thiotepa.
Topics: Administration, Intravesical; Aged; Carcinoma, Papillary; Hemorrhage; Humans; Male; Thiotepa; Urinar | 1987 |
Nephrogenic adenoma in patients with transitional cell carcinoma of the bladder receiving intravesical thiotepa.
Topics: Administration, Intravesical; Carcinoma, Transitional Cell; Humans; Male; Metaplasia; Middle Aged; P | 1988 |
The role of partial cystectomy in the management of transitional bladder cancer.
Topics: Combined Modality Therapy; Female; Humans; Male; Thiotepa; Urinary Bladder; Urinary Bladder Neoplasm | 1988 |
In vivo and in vitro enhanced antitumor effects by pentoxifylline in human cancer cells treated with thiotepa.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Cells, Cultured; Drug Synergis | 1988 |
Transitional cell carcinoma of the prostate following intravesical therapy for transitional cell carcinoma of the bladder.
Topics: Administration, Intravesical; Aged; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell | 1988 |
Effects of local chemotherapy and immunotherapy on the recurrence and progression of superficial bladder cancer.
Topics: Administration, Intravesical; BCG Vaccine; Carcinoma, Transitional Cell; Combined Modality Therapy; | 1988 |
A predictive approach to selecting the size of a clinical trial, based on subjective clinical opinion.
Topics: Administration, Intravesical; Clinical Trials as Topic; Combined Modality Therapy; Drug Administrati | 1988 |
Nonparametric methods for analyzing incomplete nondecreasing repeated measurements.
Topics: Biometry; Clinical Trials as Topic; Humans; Models, Statistical; Thiotepa; Urinary Bladder Neoplasms | 1988 |
Combined thiotepa and mitomycin C instillation therapy for low-grade superficial bladder tumor.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Transitional Cell; Cystosco | 1985 |
Long-term intravesical thiotepa treatment in patients with superficial bladder tumors and vesicoureteral reflux.
Topics: Aged; Bone Marrow; Carcinoma, Transitional Cell; Combined Modality Therapy; Female; Follow-Up Studie | 1985 |
Thiotepa versus adriamycin versus cis-platinum in the intravesical prophylaxis of superficial bladder tumors.
Topics: Cisplatin; Doxorubicin; Drug Evaluation; Humans; Neoplasm Recurrence, Local; Postoperative Care; Thi | 1985 |
Thiotepa effects on urinary cytology in the interpretation of transitional cell cancer.
Topics: Carcinoma, Transitional Cell; Cytodiagnosis; Humans; Thiotepa; Urinary Bladder; Urinary Bladder Neop | 1985 |
Intravesical chemotherapy--frequency of instillation.
Topics: Antineoplastic Agents; Doxorubicin; Drug Administration Schedule; Ethoglucid; Humans; Mitomycin; Mit | 1985 |
[Intra-cavity thermo-chemotherapy of bladder cancer: clinical use and nursing care].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Fluo | 1985 |
Review of Mayo Clinic experience with carcinoma in situ.
Topics: Administration, Topical; BCG Vaccine; Carcinoma in Situ; Doxorubicin; Hematoporphyrins; Humans; Hype | 1985 |
Management of superficial bladder cancer in a community setting.
Topics: Administration, Topical; Carcinoma in Situ; Carcinoma, Transitional Cell; Cost-Benefit Analysis; Geo | 1985 |
Intensive intravesical chemotherapy in the treatment of flat carcinoma in situ: is it safe?
Topics: Antibiotics, Antineoplastic; Carcinoma in Situ; Carcinoma, Transitional Cell; Follow-Up Studies; Hum | 1985 |
Chemotherapy for bladder cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional | 1985 |
Chemotherapy of vesical and prostatic tumours.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Bleomycin; Cobalt Isotopes; Cystitis; Daunorubic | 1971 |
Managing carcinoma of the bladder.
Topics: Aged; Biopsy; Cystoscopy; Electrosurgery; Female; Hematuria; Humans; Male; Palliative Care; Recurren | 1974 |
Renal failure associated with the use of thio-tepa.
Topics: Acute Kidney Injury; Aged; Autopsy; Carcinoma, Transitional Cell; Humans; Inflammation; Male; Neopla | 1973 |
[Experimental studies of the effect of temporary hyperthermia on bladder tumors (author's transl)].
Topics: Humans; Hyperthermia, Induced; Methods; Microscopy, Electron; Papilloma; Temperature; Thiotepa; Time | 1973 |
[The so-called benign tumors of the urinary tract].
Topics: Adult; Female; Hematuria; Humans; Kidney Neoplasms; Male; Neoplasm Recurrence, Local; Papilloma; Thi | 1973 |
[Benign bladder papillomas, prognosis and treatment. Attempt at an anatomo-clinical correlation].
Topics: Aged; Female; Humans; Male; Neoplasm Recurrence, Local; Papilloma; Prognosis; Thiotepa; Urinary Blad | 1973 |
Bladder hyperthermia in the treatment of vesical papillomatosis.
Topics: Bacitracin; Buffers; Drug Combinations; Follow-Up Studies; Hematuria; Hot Temperature; Humans; Leuko | 1973 |
[Thio-tepa in the prevention of recurrences of papillary bladder tumors].
Topics: Aged; Blood Cell Count; Blood Platelets; Carcinoma, Papillary; Female; Follow-Up Studies; Humans; Le | 1973 |
Experimental techniques for testing the sensitivity of bladder tumours to antineoplastic drugs.
Topics: Administration, Topical; Animals; Antineoplastic Agents; Carcinoma, Transitional Cell; Cell Nucleus; | 1973 |
The growth of human tumours in immunosuppressed mice and their response to chemotherapy.
Topics: Animals; Chlorambucil; Cyclophosphamide; Dactinomycin; Disease Models, Animal; Female; Fluorouracil; | 1974 |
[Usual harmlessness of endovesical instillations of thio-tepa].
Topics: Carcinoma, Papillary; Electrocoagulation; Humans; Leukopenia; Papilloma; Thiotepa; Thrombocytopenia; | 1973 |
[Spontaneously cured pancytopenia due to intravesical thio-tepa, apropos of one case].
Topics: Anemia; Female; Herpes Zoster; Humans; Leukopenia; Middle Aged; Mucous Membrane; Papilloma; Thiotepa | 1973 |
[Fatal bone marrow aplasia due to endovesical thio-tepa].
Topics: Age Factors; Aged; Anemia, Aplastic; Hematuria; Humans; Male; Mucous Membrane; Papilloma; Thiotepa; | 1973 |
Chemoprophylaxis of bladder cancer recurrence: immunological aspects.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Female; Humans; Immune Adherenc | 1974 |
[Local chemotherapy in vesical neoplasms].
Topics: Antineoplastic Agents; Daunorubicin; Doxorubicin; Drug Therapy, Combination; Humans; Neoplasm Recurr | 1974 |
Cancer chemotherapy in urology.
Topics: Adenocarcinoma; Alkylating Agents; Antibiotics, Antineoplastic; Antimetabolites; Chlorambucil; Cobal | 1971 |
Clinical and experimental projects on chemotherapy of bladder tumours.
Topics: Absorption; Alkylating Agents; Animals; Antineoplastic Agents; Cricetinae; Dogs; Drug Therapy, Combi | 1974 |
[Cytostatic prophylactic treatment of superficial bladder tumours].
Topics: Adult; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Papilloma; Thiotepa; Time Factors; Uri | 1972 |
Local chemotherapy in bladder cancer.
Topics: Bone Marrow Cells; Humans; Neoplasm Metastasis; Thiotepa; Urethral Neoplasms; Urinary Bladder Neopla | 1972 |
The role of cystography in thio-tepa toxicity.
Topics: Carcinoma, Transitional Cell; Cystoscopy; Female; Humans; Middle Aged; Poisoning; Radiography; Thiot | 1972 |
Chemotherapy in superficial neoplasms of the bladder.
Topics: Acids; Carcinoma, Papillary; Humans; Neoplasm Recurrence, Local; Papilloma; Precancerous Conditions; | 1972 |
[Effects of intravesical instillation of antitumor agents on bladder cancer].
Topics: Aged; Carcinoma, Papillary; Carcinoma, Transitional Cell; Female; Fluorouracil; Humans; Injections; | 1972 |
Multiple and recurrent epithelial tumors of the bladder in a child.
Topics: Child, Preschool; Cystoscopy; Humans; Male; Neoplasms, Multiple Primary; Papilloma; Thiotepa; Urethr | 1972 |
[The effect of the drug thio-TEPA on the microbial flora of the urine of patients with urinary bladder neoplasms].
Topics: Bacteriuria; Humans; Thiotepa; Urinary Bladder Neoplasms | 1972 |
[Local chemotherapy of papillary neoplasms of the bladder].
Topics: Antineoplastic Agents; Cyclophosphamide; Evaluation Studies as Topic; Humans; Mechlorethamine; Melph | 1973 |
Topical use of Thio-Tepa for tumours of the bladder.
Topics: Adult; Aged; Carcinoma, Papillary; Cobalt Isotopes; Electrocoagulation; Female; Humans; Male; Middle | 1965 |
Absorption and activity studies on intraluminal thio-tepa in the dog's bladder.
Topics: Absorption; Animals; Blood; Dogs; Hydrogen-Ion Concentration; In Vitro Techniques; Thiotepa; Urinary | 1965 |
Chemotherapy in bladder carcinoma.
Topics: Humans; Thiotepa; Urinary Bladder Neoplasms | 1964 |
[Severe bone marrow damage after instillation of thio tepa into the bladder].
Topics: Aged; Bone Marrow Diseases; Humans; Male; Papilloma; Thiotepa; Urinary Bladder; Urinary Bladder Neop | 1966 |
Present stage of chemotherapy in the complex treatment of urinary bladder cancer.
Topics: Humans; Thiotepa; Urinary Bladder Neoplasms | 1966 |
Intracavitary chemotherapy of diffuse non-infiltrating papillary carcinoma of the bladder.
Topics: Alkylating Agents; Carcinoma, Papillary; Female; Folic Acid Antagonists; Humans; Male; Mannitol; Met | 1966 |
The prophylactic use of thio-TEPA in transitional cell carcinoma of the bladder.
Topics: Adult; Aged; Carcinoma, Transitional Cell; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, L | 1966 |
Pancytopenia and generalized sepsis following treatment of cancer of the bladder with instillations of triethylene thiophosphoramide.
Topics: Aged; Anemia, Aplastic; Bone Marrow Examination; Carcinoma, Transitional Cell; Female; Humans; Infus | 1967 |
Severe pancytopenia associated with the use of intravesical thio-TEPA.
Topics: Aged; Anemia, Aplastic; Carcinoma, Transitional Cell; Humans; Leukocyte Count; Male; Neoplasm Recurr | 1967 |
Experimental studies of human bladder cancer: heterotransplantation to the hamster cheek pouch.
Topics: Animals; Antineoplastic Agents; Cheek; Cricetinae; Cyclophosphamide; Female; Fluorouracil; Humans; M | 1967 |
Combined radiotherapy, surgery and chemotherapy in carcinoma of the bladder.
Topics: Biopsy; Cystoscopy; Female; Humans; Male; Middle Aged; Postoperative Care; Postoperative Complicatio | 1967 |
[New experience with cytostatics, especially their intra-arterial use in bladder tumors].
Topics: Antineoplastic Agents; Electrosurgery; Humans; Injections, Intra-Arterial; Neoplasm Recurrence, Loca | 1966 |
The effects of topical THIOTEPA on the recurrence rate of superficial bladder cancers.
Topics: Aged; Female; Humans; Male; Middle Aged; Mucous Membrane; Neoplasm Recurrence, Local; Thiotepa; Urin | 1968 |
[Our previous experiences with thio-TEPA in therapy and prevention of bladder papilloma].
Topics: Adult; Aged; Female; Humans; Male; Middle Aged; Papilloma; Thiotepa; Urinary Bladder Neoplasms | 1967 |
[Therapy of urinary bladder tumors].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Azirines; Carcinoma, Papillary; Cyclophosphamide | 1967 |
The role of thiotepa instillations in bladder cancer.
Topics: Cystoscopy; Humans; Thiotepa; Urinary Bladder Neoplasms; Urinary Catheterization | 1968 |
Chemotherapy in the management of bladder tumours.
Topics: Carcinoma, Transitional Cell; Electrocoagulation; Humans; Podophyllin; Thiotepa; Triaziquone; Urinar | 1969 |
Thiotepa bladder instillations: therapy and prophylaxis for superficial bladder tumors.
Topics: Blood Platelet Disorders; Cystitis; Cystoscopy; Humans; Leukopenia; Neoplasm Recurrence, Local; Solu | 1969 |
[Management of bladder carcinoma].
Topics: Carcinoma; Cobalt Isotopes; Fluorouracil; Gold Isotopes; Humans; Radioisotope Teletherapy; Radiother | 1969 |
Current therapy for carcinoma of the bladder.
Topics: Fluorouracil; Humans; Thiotepa; Urinary Bladder Neoplasms | 1969 |
[Topical chemotherapy of bladder cancer].
Topics: Antineoplastic Agents; Humans; Methods; Thiotepa; Urinary Bladder Neoplasms | 1969 |
[Intravascular thio-tepa in the treatment of papillary neoplasms of the bladder].
Topics: Adenocarcinoma, Papillary; Carcinoma, Papillary; Humans; Papilloma; Thiotepa; Urinary Bladder Neopla | 1968 |
[Complex treatment of patients with cancer of the urinary bladder].
Topics: Humans; Thiotepa; Urinary Bladder Neoplasms | 1968 |
Instillation of thio-tepa (Tifosyl) in vesical papillomatosis.
Topics: Aged; Female; Humans; Male; Middle Aged; Papilloma; Thiotepa; Urinary Bladder Neoplasms | 1970 |
[Therapy of bladder carcinoma].
Topics: Humans; Thiotepa; Urinary Bladder Neoplasms | 1970 |
[Personal experience with thio-tepa in the treatment of papillomas and superficial carcinomas of the bladder].
Topics: Aged; Carcinoma; Carcinoma, Papillary; Female; Humans; Male; Middle Aged; Thiotepa; Urinary Bladder | 1970 |
Intracavitary chemotherapy for multiple non-invasive bladder tumours.
Topics: Alkylating Agents; Carcinoma, Papillary; Humans; Leukopenia; Neoplasm Recurrence, Local; Thiotepa; U | 1971 |
Intravesical thiotepa in the treatment of transitional cell bladder carcinoma.
Topics: Aged; Bone Marrow; Carcinoma, Transitional Cell; Female; Humans; Male; Middle Aged; Neoplasm Recurre | 1971 |
[Chemotherapy of bladder cancer].
Topics: Alkaloids; Alkylating Agents; Antimetabolites; Drug Synergism; Fluorouracil; Humans; Mitomycins; Thi | 1971 |
[Experimental animal and clinical studies of the absorption of trisaziridylthiophosphoric acid (Thio-Thepa) from the bladder].
Topics: Absorption; Animals; Cystitis; Humans; Male; Papilloma; Rabbits; Thiotepa; Urinary Bladder; Urinary | 1970 |
Absorption studies on intraluminal thio-tepa for topical cytostatic treatment of low-stage bladder tumors.
Topics: Body Fluids; Bone Marrow; Cystitis; Epithelium; Humans; Methods; Papilloma; Pyridines; Thiotepa; Uri | 1971 |
[Cytostatic topical therapy and prevention of recurrence in bladder papillomatosis].
Topics: Antineoplastic Agents; Humans; Papilloma; Secondary Prevention; Thiotepa; Urinary Bladder Neoplasms | 1971 |
[Verification of the effectiveness of Thio-Tepa on tumor tissue in local chemotherapy of bladder papillomatosis].
Topics: Cell Nucleus; Evaluation Studies as Topic; Histocytochemistry; Humans; Papilloma; Thiotepa; Time Fac | 1970 |